US20120202766A1 - N4-acylcytosine nucleosides for treatment of viral infections - Google Patents

N4-acylcytosine nucleosides for treatment of viral infections Download PDF

Info

Publication number
US20120202766A1
US20120202766A1 US13/371,654 US201213371654A US2012202766A1 US 20120202766 A1 US20120202766 A1 US 20120202766A1 US 201213371654 A US201213371654 A US 201213371654A US 2012202766 A1 US2012202766 A1 US 2012202766A1
Authority
US
United States
Prior art keywords
hydrogen
fluorine
pharmaceutically acceptable
active compound
limited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/371,654
Inventor
Michael J. Otto
Junxing Shi
Kyoichi A. Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Pharmasset LLC
Original Assignee
Pharmasset Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Inc filed Critical Pharmasset Inc
Priority to US13/371,654 priority Critical patent/US20120202766A1/en
Assigned to GILEAD PHARMASSET LLC reassignment GILEAD PHARMASSET LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PHARMASSET, INC.
Publication of US20120202766A1 publication Critical patent/US20120202766A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Definitions

  • the present invention is directed to compounds, methods and compositions for the treatment or prevention of viral infections using nucleoside analogues. More specifically, the invention describes N.sup.4-acyl-substituted cytosine nucleoside analogues, pharmaceutically acceptable salts, prodrugs, or other derivatives thereof, and the use thereof in the treatment of a viral infection, and in particular a human immunodeficiency virus (HIV) or hepatitis B virus (HBV) infection.
  • HIV human immunodeficiency virus
  • HBV hepatitis B virus
  • HIV human immunodeficiency virus
  • HBV hepatitis B virus
  • HBV infection can lead to acute hepatitis and liver damage, resulting in abdominal pain, jaundice and elevated blood levels of certain enzymes. HBV can cause fulminant hepatitis, a rapidly progressive, often fatal form of the disease in which large sections of the liver are destroyed.
  • Chronic infections can lead to chronic persistent hepatitis.
  • Patients infected with chronic persistent HBV are most common in developing countries. By mid-1991, there were approximately 225 million chronic carriers of HBV in Asia alone, and worldwide, almost 300 million carriers. Chronic persistent hepatitis can cause fatigue, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.
  • HBV infection In Western, industrialized countries, the high-risk group for HBV infection includes those in contact with HBV carriers or their blood samples.
  • the epidemiology of HBV is very similar to that of HIV/AIDS, which is a reason why HBV infection is common among patients infected with HIV or suffering from AIDS.
  • HBV is more contagious than HIV.
  • these synthetic nucleosides After phosphorylation to the 5′-triphosphate by cellular kinases, these synthetic nucleosides are incorporated into a growing strand of viral DNA, causing chain termination, because they lack a 3′-hydroxyl group. Some nucleosides also inhibit the viral enzyme reverse transcriptase.
  • 3TC (lamivudine) and interferon are currently the only FDA-approved drugs for the treatment of HBV infection. Viral resistance develops within 6 months of 3TC treatment in about 14% of patients.
  • Cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is currently in clinical trials for the treatment of HIV and separately for HBV by Triangle Pharmaceuticals, Inc. See Schinazi et al. (1992) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine. Antimicrob. Agents Chemother. 36, 2423-2431; U.S. Pat. Nos. 5,210,085; 5,914,331; 5,814,639; WO 91/11186; and WO 92/14743.
  • ⁇ -D-2′,3′-Dideoxy-2′,3′-didehydro-5-fluorocytidine (d4FC) and its use to treat hepatitis B was first described in Example 2 of European Pat. Application No. 0 409 227 A2 (Ajinomoto Co., Inc.). Netherlands Pat. No. 8901258 (Stichting Rega V.Z.W.) discloses generally 5-halogeno-2′,3′-dideoxy-2′,3′-didehydrocytidine derivatives for use in treating HIV and HBV. ⁇ -D- and ⁇ -L-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine were further described in U.S. Pat.
  • U.S. Pat. No. 5,703,058 claims a method for the treatment of HIV and/or HBV infection that includes administering an effective amount of ⁇ -L-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, cis-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane, 9-[4-(hydroxymethyl)-2-cyclopenten-1-yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]-guanine (acyclovir), interferon, 3′-deoxy-3′-azido-thymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), ( ⁇ )-2′
  • U.S. Pat. No. 5,905,070 claims a method for the treatment of HIV and HBV infection that includes administering an effective amount of ⁇ -D-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, cis-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane, 9-[4-(hydroxy-methyl)-2-cyclopenten-1-yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir), interferon, 3′-deoxy-3′-azido-thymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), ( ⁇ )-2′-fluoro-5-methyl- ⁇ -L-ara-uridine (L-FMAU) or 2′,3
  • N 4 -acyl-cytosine nucleosides and in particular, N 4 -acyl-2′,3′-dideoxy-5-fluorocytidine and N 4 -acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-cytidine, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of HIV and/or HBV infection in a host, and in particular, a human, is provided that includes administering an effective amount of a N 4 -acyl-cytosine nucleoside.
  • the active compound is of formula (I) or (II):
  • R 2 cannot be an alkyl, alkoxyalkyl (such as methoxymethyl), aralkyl (such as benzyl or substituted benzyl), aryloxyalkyl (such as phenoxymethyl) or aryl (including but not limited to a phenyl optionally substituted with halogen (F, Cl, Br, I), alkyl (including but not limited to C 1 , C 2 , C 3 , and C 4 ) or alkoxy (including but not limited to C 1 , C 2 , C 3 , and C 4 )).
  • alkoxyalkyl such as methoxymethyl
  • aralkyl such as benzyl or substituted benzyl
  • aryloxyalkyl such as phenoxymethyl
  • aryl including but not limited to a phenyl optionally substituted with halogen (F, Cl, Br, I)
  • alkyl including but not limited to C 1 , C 2 , C 3 , and C 4
  • the compound of the present invention can be in the form of the isolated ⁇ -L- or ⁇ -D-configuration, or a mixture thereof, including but not limited to a racemic mixture.
  • Y is CH 2 and both R 3 and R 3′ groups are hydrogen, forming a d2 nucleoside (i.e., a 2′,3′-dideoxy nucleoside).
  • the active compound is ⁇ -D-N 4 -p-iodobenzoyl-2′,3′-dideoxy-5-fluorocytidine.
  • active compounds include ⁇ -D-N 4 -p-fluoro-benzoyl-2′,3′-dideoxy-5-fluorocytidine, ⁇ -D-N 4 -p-chlorobenzoyl-2′,3′-dideoxy-5-fluoro-cytidine, ⁇ -D-N 4 -p-bromobenzoyl-2′,3′-dideoxy-5-fluorocytidine, ⁇ -D-N 4 -p-ethylbenzoyl-2′,3′-dideoxy-5-fluorocytidine, and ⁇ -D-N 4 -p-t-butylbenzoyl-2′,3′-dideoxy-5-fluoro-cytidine.
  • the active compound is ⁇ -D-N 4 -p-bromobenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine.
  • active compounds include ⁇ -D-N 4 -p-fluorobenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, ⁇ -D-N 4 -p-chlorobenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, ⁇ -D-N 4 -p-iodobenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, ⁇ -D-N 4 -p-ethylbenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and ⁇ -D-N 4 -p-eth
  • 2′,3′-dideoxy-N 4 -acyl-cytosinenucleosides and 2′,3′-didehydro-2′,3′-dideoxy-N 4 -acyl-cytosinenucleosides are inhibitors of HBV. Therefore, these compounds can also be used to treat patients that are co-infected with both HIV and HBV.
  • the present invention provides a compound, method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a compound, method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a compound, method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a compound, method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient for the treatment of a host infected with HIV or HBV.
  • a compound, method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • FIG. 1 is a non-limiting example of the synthesis of active compounds of the present invention, and in particular, the synthesis of ⁇ -D-N 4 -acyl-2′,3′-dideoxy-5-fluorocytidine and ⁇ -D-N 4 -acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine nucleosides.
  • FIG. 2 is a graphic representation of the anti-HBV activity of selected N 4 -acyl-substituted ⁇ -D-2′,3′-dideoxy- and ⁇ -D-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine analogues.
  • N 4 -acyl-cytosine nucleosides and in particular, N 4 -acyl-2′,3′-dideoxy-5-fluorocytidine and N 4 -acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of a host, and in particular, a human, infected with HIV and/or HBV, is provided that includes administering an effective amount of an N 4 -acyl-cytosine nucleosides.
  • the present invention also provides a method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient.
  • a method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • the active compound is of formula (I) or (II):
  • the compound of the present invention can be in the form of the ⁇ -L- or ⁇ -D-configuration, or a racemic mixture.
  • R 2 cannot be an alkyl, alkoxyalkyl (such as methoxymethyl), aralkyl (such as benzyl or substituted benzyl), aryloxyalkyl (such as phenoxymethyl) or aryl (including but not limited to a phenyl optionally substituted with halogen (F, Cl, Br, I), alkyl (including but not limited to C 1 , C 2 , C 3 , and C 4 ) or alkoxy (including but not limited to C 1 , C 2 , C 3 , and C 4 )).
  • alkoxyalkyl such as methoxymethyl
  • aralkyl such as benzyl or substituted benzyl
  • aryloxyalkyl such as phenoxymethyl
  • aryl including but not limited to a phenyl optionally substituted with halogen (F, Cl, Br, I)
  • alkyl including but not limited to C 1 , C 2 , C 3 , and C 4
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula, its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its Pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (H), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (H), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • R 2 is a phenyl moiety optionally substituted with 2,6- dialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • the active compound is ⁇ -D-2′,3′-dideoxy-5-fluoro-N 4 -(4-iodobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-dideoxy-5-fluoro-N 4 -(4-fluorobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-chlorobenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-bromobenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-dideoxy-5-fluoro-N 4 -(3-fluorobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(3-chlorobenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(3-bromobenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-dideoxy-5-fluoro-N 4 -(4-nitrobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-dideoxy-5-fluoro-N 4 -p-toluoylcytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-dideoxy-5-fluoro-N 4 -(m-toluoyl)cytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-dideoxy-N 4 -(4-ethylbenzoyl)-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-dideoxy-5-fluoro-N 4 -(4-propylbenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-tert-butylbenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-dideoxy-5-fluoro-N 4 -(2-thiophenecarbonyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(benzo-[b]-thiophene-2-carbonyl)-2′3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(cyclohexane-carbonyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N 4 -(4-iodobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N 4 -(4-fluorobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-chlorobenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-bromobenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -p-anisoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N 4 -(3-nitrobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N 4 -p-toluoylcytidine of the structure:
  • the active compound is ⁇ -D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N 4 -m-toluoylcytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-t-butylbenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -cyclopentanecarbonyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the active compound is (cyclohexanecarbonyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • the compounds of the present invention have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers or enantiomers, with all isomeric forms being included in the present invention. Some compounds may exhibit polymorphism.
  • the present invention encompasses racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein.
  • the optically active forms can be prepared by, for example, resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution.
  • Examples of methods to obtain optically active materials include at least the following.
  • Chiral chromatography including but not limited to simulated moving bed chromatography, is used in one embodiment.
  • a wide variety of chiral stationary phases are commercially available.
  • both R′′ can be carbon, both R′′ can be nitrogen, or one R′′ can be carbon and the other R′′ nitrogen.
  • the term “substantially free of” or “substantially in the absence of refers to a nucleoside composition that includes at least 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside.
  • the compounds are substantially free of enantiomers.
  • isolated refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the nucleoside, the remainder comprising other chemical species or enantiomers.
  • alkyl refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon. The term includes both substituted and unsubstituted alkyl groups.
  • the alkyl group may be optionally substituted with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to but limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those
  • C(alkyl range) independently includes each member of that class as if specifically and separately set out.
  • C 1-22 independently represents each species that falls within the scope.
  • Alkyl groups include, but are not limited to the radicals of methane, ethane, propane, cyclopropane, 2-methylpropane(isobutane), n-butane, 2,2-dimethylpropane(neopentane), cytobutane, 1,1 dimethylcyclopropane, 2-methylbutane, trans-1,2-dimethylcyclopropane, ethylcyclopropane, n-pentane, methylcyclobutane, cis-1,2-dimethylcyclopropane, spiropentane, cyclopentane, 2,2-dimethylbutane, 1,1,2-trimethylcyclopropane, 2,3-dimethylbutane, 2-methylpentan
  • alkenyl refers to an unsaturated, hydrocarbon radical, linear or branched, in so much as it contains one or more double bonds.
  • the alkenyl group disclosed herein can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxi
  • Non-limiting examples of alkenyl groups include methylene, ethylene, methylethylene, isopropylidene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3-propane-diyl, 1,2-propane-diyl, 1,3-butane-diyl, and 1,4-butane-diyl.
  • alkynyl refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds.
  • the alkynyl group may be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to hydroxyl, halo (F, Cl, Br, I), perfluoro alkyl including but not limited to trifluoromethyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, acyl, amido, carboxamido, carboxylate, thiol, alkylthio, azido, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second
  • Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3-methylbutyn-1-yl, hexyn-1-yl, hexyn-2-yl, and hexyn-3-yl, 3,3-dimethylbutyn-1-yl radicals.
  • alkylamino or “arylamino” refers to an amino group that has one or two alkyl or aryl substituents, respectively.
  • protected refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes.
  • oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
  • aryl alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused.
  • Non-limiting examples of aryl include phenyl, biphenyl, or naphthyl, or the following aromatic group that remains after the removal of a hydrogen from the aromatic ring: benzene, toluene, ethylbenzene, 1,4-xylene, 1,3-xylene, 1,2-xylene, isopropylbenzene(cumene), n-propylbenzene, 1-ethyl-3-methylbenzene(m-ethyltoluene), 1-ethyl-4-methylbenzene(p-ethyltoluene), 1,3,5-trimethylbenzene(mesitylene), 1-ethyl-2-methylbenzene(o-ethyltoluene), tert-butylbenzene,
  • aryl includes both substituted and unsubstituted moieties.
  • the aryl group may be optionally substituted with any moiety that does not adversely affect the process, including but not limited to but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group
  • Non-limiting examples of substituted aryl include heteroarylamino, N-aryl-N-alkylamino, N-heteroarylamino-N-alkylamino, heteroaralkoxy, arylamino, aralkylamino, arylthio, monoarylamidosulfonyl, arylsulfonamido, diarylamidosulfonyl, monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, hydroxyaralkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially
  • halo includes chloro, bromo, iodo and fluoro.
  • acyl refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including but not limited to methoxymethyl, aralkyl including but not limited to benzyl, aryloxyalkyl such as phenoxymethyl, aryl including but not limited to phenyl optionally substituted with halogen (F, Cl, Br, I), alkyl (including but not limited to C 1 , C 2 , C 3 , and C 4 ) or alkoxy (including but not limited to C 1 , C 2 , C 3 , and C 4 ), sulfonate esters such as alkyl or aralkyl sulphonyl including but not limited to methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trial
  • alkoxy and “alkoxyalkyl” embrace linear or branched oxy-containing radicals having alkyl moieties, such as methoxy radical.
  • alkoxyalkyl also embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals.
  • the “alkoxy” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide “haloalkoxy” radicals.
  • radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropoxy.
  • alkylamino denotes “monoalkylamino” and “dialkylamino” containing one or two alkyl radicals, respectively, attached to an amino radical.
  • arylamino denotes “monoarylamino” and “diarylamino” containing one or two aryl radicals, respectively, attached to an amino radical.
  • aralkylamino embraces aralkyl radicals attached to an amino radical.
  • aralkylamino denotes “monoaralkylamino” and “diaralkylamino” containing one or two aralkyl radicals, respectively, attached to an amino radical.
  • aralkylamino further denotes “monoaralkyl monoalkylamino” containing one aralkyl radical and one alkyl radical attached to an amino radical.
  • heteroatom refers to oxygen, sulfur, nitrogen and phosphorus.
  • heteroaryl or “heteroaromatic,” as used herein, refer to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
  • heterocyclic refers to a nonaromatic cyclic group wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring.
  • heteroaryl and heterocyclic groups include furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, imidazole
  • the heteroaromatic group can be optionally substituted as described above for, aryl.
  • the heterocyclic or heteroaromatic group can be optionally substituted with one or more substituent selected from halogen (F, Cl, Br, I), haloalkyl, alkyl, alkoxy, hydroxy, carboxyl derivatives, amido, amino, alkylamino, dialkylamino.
  • the heteroaromatic can be partially or totally hydrogenated as desired.
  • dihydropyridine can be used in place of pyridine. Functional oxygen and nitrogen groups on the heterocyclic or heteroaryl group can be protected as necessary or desired.
  • Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl.
  • the heterocyclic or heteroaromatic group can be substituted with any moiety that does not adversely affect the reaction, including but not limited to but not limited to those described above for aryl.
  • the term “host,” as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including but not limited to cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds of the present invention.
  • the term host specifically refers to infected cells, cells transfected with all or part of the viral genome and animals, in particular, primates (including but not limited to chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as chimpanzees).
  • pharmaceutically acceptable salt or prodrug is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a nucleoside compound which, upon administration to a patient, provides the nucleoside compound.
  • Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art.
  • Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention.
  • prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
  • Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
  • the compounds of this invention possess antiviral activity against Flaviviridae, or are metabolized to a compound that exhibits such activity.
  • Prodrugs also include natural or unnatural amino acid esters of the disclosed nucleosides (see, e.g., European Patent Specification No. 99493, the text of which is incorporated by reference, which describes amino acid esters of acyclovir, specifically the glycine and alanine esters which show improved water-solubility compared with acyclovir itself, and U.S. Pat. No. 4,957,924 (Beauchamp), which discloses the valine ester of acyclovir, characterized by side-chain branching adjacent to the ⁇ -carbon atom, which showed improved bioavailability after oral administration compared with the alanine and glycine esters).
  • a process for preparing such amino acid esters is disclosed in U.S. Pat.
  • Suitable inorganic salts may also be formed, including but not limited to, sulfate, nitrate, bicarbonate and carbonate salts.
  • salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid, affording a physiologically acceptable anion.
  • a sufficiently basic compound such as an amine
  • suitable acid affording a physiologically acceptable anion.
  • Alkali metal e.g., sodium, potassium or lithium
  • alkaline earth metal e.g., calcium
  • nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside.
  • a number of nucleotide prodrug ligands are known.
  • alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide.
  • substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including but not limited to sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones & N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed nucleosides to achieve a desired effect.
  • the active nucleoside can also be provided as a 5′-phosphoether lipid or a 5′-ether lipid, as disclosed in the following references, which are incorporated by reference: Kucera, L. S., N. Iyer, E. Leake, A. Raben, Modest E. K., D. L. W., and C. Piantadosi, “Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation,” AIDS Res. Hum. Retroviruses, 1990, 6, 491-501; Piantadosi, C., J. Marasco C. J., S. L. Morris-Natschke, K. L. Meyer, F. Gumus, J. R. Surles, K. S.
  • Nonlimiting examples of US patents that disclose suitable lipophilic substituents that can be covalently incorporated into the nucleoside, preferably at the 5′-OH position of the nucleoside or lipophilic preparations include U.S. Pat. No. 5,149,794 (Yatvin et al.); U.S. Pat. No. 5,194,654 (Hostetler et al.), U.S. Pat. No. 5,223,263 (Hostetler et al.); U.S. Pat. No. 5,256,641 (Yatvin et al.); U.S. Pat. No. 5,411,947 (Hostetler et al.); U.S. Pat. No.
  • the active compound or its prodrug or salt can be administered in combination or alternation with another antiviral agent, such as another active anti-HIV or anti-HBV agent, including but not limited to those of the formulae above, others listed below or known in the art.
  • another antiviral agent such as another active anti-HIV or anti-HBV agent, including but not limited to those of the formulae above, others listed below or known in the art.
  • effective dosages of two or more agents are administered together, whereas during alternation therapy, an effective dosage of each agent is administered serially.
  • the dosage will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject; specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
  • antiviral agents that can be used in combination with the compounds disclosed herein include those in the tables below.
  • HIV Therapies Protease Inhibitors (PIs) Brand Pharmaceutical Name Generic Name Abbreviation Company Invirase ® saquinavir (Hard SQV (HGC) Hoffmann-La Roche Gel Cap) Fortovase ® saquinavir (Soft SQV (SGC) Hoffmann-La Roche Gel Cap) Norvir ® ritonavir RTV Abbott Laboratories Crixivan ® indinavir IDV Merck & Co.
  • HGC Hard SQV
  • SGC Soft SQV
  • HIV Therapies Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Brand Pharmaceutical Name Generic Name Abbreviation Company Retrovir ® zidovudine AZT or ZDV GlaxoSmithKline Epivir ® lamivudine 3TC GlaxoSmithKline Combivir ® zidovudine + AZT + 3TC GlaxoSmithKline lamivudine Trizivir ® abacavir + ABC + AZT + GlaxoSmithKline zidovudine + 3TC lamivudine Ziagen ® abacavir ABC GlaxoSmithKline Hivid ® zalcitabine ddC Hoffmann-La Roche Videx ® didanosine: buffered ddI Bristol-Myers versions Squibb Videx ® EC didanosine: delayed- ddI Bristol-Myers release capsules Squibb Zerit ® stavudine d4T Bristol-Myers S
  • NRTIs Non-Nucleoside Reverse Transcriptase Inhibitors Brand Name Generic Name Abbreviation Pharmaceutical Company Viramune ® nevirapine NVP Boehringer Ingelheim Rescriptor ® delavirdine DLV Pfizer Sustiva ® efavirenz EFV Bristol-Myers Squibb (+)-calanolide A Sarawak Medichem capravirine CPV Pfizer Bristol-Myers Squibb Tibotec-Virco Group Tibotec-Virco Group
  • HIV Therapies Other Classes of Drugs Pharmaceutical Brand Name Generic Name Abbreviation Company Viread TM tenofovir disoproxil TDF or Bis(POC) Gilead Sciences fumarate (DF) PMPA
  • HIV Therapies Immune-Based Therapies Brand Pharmaceutical Name Generic Name Abbreviation Company Proleukin ® aldesleukin, or IL-2 Chiron Corporation Interleukin-2 Remune ® HIV-1 The Immune Immunogen, or Response Salk vaccine Corporation HollisEden Pharmaceuticals
  • HIV Therapies Treatments for Side Effects Pharmaceutical Brand Name Generic Name Side Effect Company Procrit ® epoetin alfa Anemia Ortho Biotech (erythropoietin) Serostim ® somatropin, or Lipodystrophy Serono human growth Laboratories hormone
  • the compounds of the invention may be employed together with at least one other antiviral agent chosen from reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors and polymerase inhibitors.
  • compounds according to the present invention can be administered in combination or alternation with one or more anti-retrovirus, anti-HBV, anti-HCV or anti-herpetic agent or interferon, anti-cancer or antibacterial agents, including but not limited to other compounds of the present invention.
  • Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents according to the present invention by reducing the metabolism, catabolism or inactivation of other compounds and as such, are co-administered for this intended effect.
  • Host including but not limited to humans, infected with a human immunodeficiency virus, a hepatitis virus, or a gene fragment thereof, can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent.
  • the active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
  • a preferred dose of the compound for an HIV or HBV infection will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day.
  • the effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
  • the compound is conveniently administered in unit any suitable dosage form, including but not limited to but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form.
  • An oral dosage of 50-1000 mg is usually convenient.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 ⁇ M, preferably about 1.0 to 10 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
  • the concentration of active compound in the drug composition will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
  • the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such
  • the compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compound(s), sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories or other antivirals, including but not limited to other nucleoside compounds.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for the adjustment of tonicity, such as sodium chloride or dextrose.
  • the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • preferred carriers are physiological saline or phosphate buffered saline (PBS).
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including but not limited to implants and microencapsulated delivery systems.
  • a controlled release formulation including but not limited to implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid.
  • enterically coated compounds can be used to protect cleavage by stomach acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Suitable materials can also be obtained commercially.
  • Liposomal suspensions are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (incorporated by reference). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container.
  • appropriate lipid(s) such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol
  • aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container.
  • the container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • a method for the facile preparation of N 4 -acyl-substituted 2′,3′-dideoxy-5-fluorocytidine and 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine nucleosides is also provided.
  • the method includes condensation of a 5′-O-silyl protected 2′,3′-dideoxy-5-fluorocytidine or a 5′-O-silyl protected 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, with either a carboxylic acid chloride, or carboxylic acid anhydride, or a carboxylic acid, followed by desilylation.
  • the other N 4 -acyl-substituted cytosine nucleosides can be synthesized using the similar approaches.
  • N 4 -acyl-substituted 2′,3′-dideoxy-5-fluorocytidine and 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine nucleosides disclosed herein can be prepared as described in detail below, or by other assays known to those skilled in the art.
  • Anhydrous solvents were purchased from Aldrich Chemical Company, Inc. (Milwaukee). Melting points (mp) were determined on an Electrothermal digit melting point apparatus and are uncorrected. 1 H and 13 C NMR spectra were taken on a Varian Unity Plus 400 spectrometer at room temperature and reported in ppm downfield from internal tetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSY were performed to confirm proton assignments. Signal multiplicities are represented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quadruplet), br (broad), bs (broad singlet), m (multiplet).
  • Anti-HIV-1 activity of the compounds was determined in human peripheral blood mononuclear (PBM) cells as described previously (Schinazi R. F., McMillan A., Cannon D., Mathis R., Lloyd R. M. Jr., Peck A., Sommadossi J.-P., St. Clair M., Wilson J., Furman P. A., Painter G., Choi W.-B., Liotta D. C. Antimicrob. Agents Chemother. 1992, 36, 2423; Schinazi R. F., Sommadossi J.-P., Saalmann V., Cannon D., Xie M.-Y., Hart G., Smith G., Hahn E.
  • the potency of the compounds was determined by measurement of viral RNA accumulation in HIV-1 RF infected MT-2 cells (Bacheler L T, Paul M, Otto M J, Jadhav P K, Stone B A & Miller J A (1994) An assay for HIV RNIn infected cell lysates, and its use for rapid evaluation of antiviral efficacy. Antivir. Chem. Chemother. 5:111-121).
  • the virus titer was established to determine the dilution producing 15 to 30 ng/RNA per well of HIV RNIn 3 days of infection.
  • HIV-1 RNA was quantified using biotinylated capture and alkaline phosphatase-derivatized reporter oligonucleotides as described previously (Charvet A-S, Camplo M, Faury P, Graciet J C, Mourier N, Chermann J C & Kraus J L (1994) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2′,3′-dideoxy-3′-thiacytidine conjugates. J. Med. Chem. 37:2216-2223).
  • the anti-HBV activity of the compounds was determined by treating the AD-38 cell line carrying wild type HBV under the control of tetracycline (Ladner S. K., Otto M. J., Barker C. S., Zaifert K., Wang G. H., Guo J. T., Seeger C. & King R. W. Antimicrob. Agents Chemother. 1997, 41, 1715-1720). Removal of tetracycline from the medium [Tet ( ⁇ )] results in the production of HBV. The levels of HBV in the culture supernatant fluids from cells treated with the compounds were compared with that of the untreated controls. Control cultures with tetracycline [Tet (+)] were also maintained to determine the basal levels of HBV expression. 3TC was included as positive control (see Tables 1, 2).
  • the toxicity of, the compounds was assessed in Vero, human PBM, CEM (human lymphoblastoid), MT-2, and HepG2 cells, as described previously (Schinazi R. F., Sommadossi J.-P., Saalmann V., Cannon D. L., Xie M.-Y., Hart G. C., Smith G. A. & Hahn E. F. Antimicrob Agents Chemother. 1990, 34, 1061-1067). Cycloheximide was included as positive cytotoxic control, and untreated cells exposed to solvent were included as negative controls. The cytotoxicity IC 50 was obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M. S. & Schinazi R. F. Antiviral Res. 1994, 25, 1-11) (see Tables 1, 2).

Abstract

The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehyd-ro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Description

  • The present application claims priority to U.S. patent application Ser. No. 10/318,511 filed on Dec. 13, 2002, which claimed priority to U.S. Patent Application Ser. No. 60/341,555 filed on Dec. 14, 2001.
    • FIELD OF THE INVENTION
  • The present invention is directed to compounds, methods and compositions for the treatment or prevention of viral infections using nucleoside analogues. More specifically, the invention describes N.sup.4-acyl-substituted cytosine nucleoside analogues, pharmaceutically acceptable salts, prodrugs, or other derivatives thereof, and the use thereof in the treatment of a viral infection, and in particular a human immunodeficiency virus (HIV) or hepatitis B virus (HBV) infection.
    • BACKGROUND OF THE INVENTION
  • In 1981, acquired immune deficiency syndrome (AIDS) was identified as a disease that severely compromises the human immune system, and that without exception leads to death. In 1983, the etiological cause of AIDS was determined to be what is now known as human immunodeficiency virus (HIV).
  • Another virus that causes a serious human health problem is the hepatitis B virus (HBV). HBV is second only to tobacco as a cause of human cancer. The mechanism by which HBV induces cancer is unknown. It is postulated that it may directly trigger tumor development, or indirectly trigger tumor development through chronic inflammation, cirrhosis, and cell regeneration associated with the infection.
  • After a 2- to 6-month incubation period, during which the host is typically unaware of the infection, HBV infection can lead to acute hepatitis and liver damage, resulting in abdominal pain, jaundice and elevated blood levels of certain enzymes. HBV can cause fulminant hepatitis, a rapidly progressive, often fatal form of the disease in which large sections of the liver are destroyed.
  • Patients typically recover from the acute phase of HBV infection. In some patients, however, high levels of viral antigen persist in the blood for an extended, or indefinite, period, causing a chronic infection. Chronic infections can lead to chronic persistent hepatitis. Patients infected with chronic persistent HBV are most common in developing countries. By mid-1991, there were approximately 225 million chronic carriers of HBV in Asia alone, and worldwide, almost 300 million carriers. Chronic persistent hepatitis can cause fatigue, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.
  • In Western, industrialized countries, the high-risk group for HBV infection includes those in contact with HBV carriers or their blood samples. The epidemiology of HBV is very similar to that of HIV/AIDS, which is a reason why HBV infection is common among patients infected with HIV or suffering from AIDS. However, HBV is more contagious than HIV.
  • In 1985, it was reported that the synthetic nucleoside 3′-azido-3′-deoxythymidine (AZT) inhibited the replication of HIV. Since then, several other synthetic nucleosides, including but not limited to 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T), (−)-2′,3′-dideoxy-3′-thiacytidine (3TC), and (−)-carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (carbovir) and its prodrug abacavir, have proven effective against HIV. After phosphorylation to the 5′-triphosphate by cellular kinases, these synthetic nucleosides are incorporated into a growing strand of viral DNA, causing chain termination, because they lack a 3′-hydroxyl group. Some nucleosides also inhibit the viral enzyme reverse transcriptase.
  • 3TC (lamivudine) and interferon are currently the only FDA-approved drugs for the treatment of HBV infection. Viral resistance develops within 6 months of 3TC treatment in about 14% of patients.
  • Cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC) is currently in clinical trials for the treatment of HIV and separately for HBV by Triangle Pharmaceuticals, Inc. See Schinazi et al. (1992) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine. Antimicrob. Agents Chemother. 36, 2423-2431; U.S. Pat. Nos. 5,210,085; 5,914,331; 5,814,639; WO 91/11186; and WO 92/14743.
  • The success of 2′,3′-dideoxy- and 2′,3′-didehydro-2,′3′-dideoxy-nucleosides (referred to as a “ddN” or “d2N” nucleoside and a “d4N” nucleoside, respectively) in inhibiting the replication of HIV in vivo or in vitro has led a number of researchers to design and test a variety of modified d2- and d4-nucleosides. One modification has been the replacement of the 5-hydrogen on cytosine nucleosides with fluorine, resulting in several 5-fluorocytosine nucleosides with antiviral activity, including but not limited to β-D- and β-L-2′,3′-dideoxy-5-fluorocytine (β-D-D2FC and β-L-D2FC) (U.S. Pat. Nos. 4,788,181 and 6,156,737).
  • β-D-2′,3′-Dideoxy-2′,3′-didehydro-5-fluorocytidine (d4FC) and its use to treat hepatitis B was first described in Example 2 of European Pat. Application No. 0 409 227 A2 (Ajinomoto Co., Inc.). Netherlands Pat. No. 8901258 (Stichting Rega V.Z.W.) discloses generally 5-halogeno-2′,3′-dideoxy-2′,3′-didehydrocytidine derivatives for use in treating HIV and HBV. β-D- and β-L-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine were further described in U.S. Pat. Nos. 5,703,058; 5.905,070; 6,232,300; and 5,561,120. U.S. Pat. No. 5,703,058 claims a method for the treatment of HIV and/or HBV infection that includes administering an effective amount of β-L-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, cis-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane, 9-[4-(hydroxymethyl)-2-cyclopenten-1-yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]-guanine (acyclovir), interferon, 3′-deoxy-3′-azido-thymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), (−)-2′-fluoro-5-methyl-β-L-ara-uridine (L-FMAU) or 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). U.S. Pat. No. 5,905,070 claims a method for the treatment of HIV and HBV infection that includes administering an effective amount of β-D-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, cis-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane, 9-[4-(hydroxy-methyl)-2-cyclopenten-1-yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir), interferon, 3′-deoxy-3′-azido-thymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), (−)-2′-fluoro-5-methyl-β-L-ara-uridine (L-FMAU) or 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T). U.S. Pat. No. 6,232,300 claims a method to treat HIV with β-D-d4FC.
  • Modification of the amino group of antiviral cytosine nucleosides has not been fully explored. Only a few N4-substituted cytosine 2′,3′-dideoxy nucleosides and N4-substituted cytosine 2′,3′-didehydro-2′,3′-dideoxy nucleosides have been reported. These include N4-benzoyl-2′,3′-didehydro-2,′3-dideoxycytidine (Kawaguchi et al., Studies on 2′,3′-dideoxy-2′,3′-didehydropyrimidine nucleosides. II. N4-benzoyl-2′,3′-dideoxy-2′,3′-didehydrocytidine as a prodrug of 2′,3′-dideoxy-2′,3′-didehydrocytidine (DDCN), Chem. Pharm. Bull. (1989), 37(9), 2547-9), N4-benzoyl-2′,3′-dideoxycytidine (Gulbis et al. (1993) Structure of a dideoxynucleoside active against the HIV (AIDS) virus. Acta Cryst. C49, 1095-1097), N4-acetyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and N4-isopropyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (Shi et al. (1999)) Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (d4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. J. Med. Chem. 42, 859-867). Of the sugar-modified cytosine nucleosides, some N4-acyl and imine-substituted-2′,3′-dideoxy-3′-C-hydroxymethylcytidine analogues have been synthesized (Mauldin et al. (1998) Synthesis and antiviral activity of prodrugs of the nucleoside 1-[2′,3′-dideoxy-3′-C-(hydroxymethyl)-β-D-erythropentofuranosyl]cytosine. Bioorg. Med. Chem. 6, 577-585), and some N4-acetyl- and phosphonoacetyl-2′,3′-dideoxy-3′-thiacytidine nucleosides have been prepared (Charvet et al. (1993) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2′,3′-dideoxy-3′-thiacytidine conjugates. J. Med. Chem. 37, 2216-2223).
  • Therefore, it is an object of the present invention to provide a method and composition for the treatment or prevention of HIV infection in human patients.
  • It is another object of the present invention to provide a method and composition for the treatment or prevention of HBV infection in human patients or other host animals.
  • It is still another object of the present invention to provide a method and composition for the treatment or prevention of HIV and HBV infection in human patients or other host animals.
    • SUMMARY OF THE INVENTION
  • It has been found that certain N4-acyl-cytosine nucleosides, and in particular, N4-acyl-2′,3′-dideoxy-5-fluorocytidine and N4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-cytidine, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of HIV and/or HBV infection in a host, and in particular, a human, is provided that includes administering an effective amount of a N4-acyl-cytosine nucleoside.
  • In one embodiment of the invention, the active compound is of formula (I) or (II):
  • Figure US20120202766A1-20120809-C00001
  • or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O, S, NR5, CH2, CHF or CF2;
    • ii) Y is CH2, CHF or CF2;
    • iii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), CN, CF3, N3, NO2, aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12) and acyl (including but not limited to C2, C3, C4, C5, and C6);
    • iv) R2 is chosen from alkyl (including but not limited to C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), alkenyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), alkynyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), hydroxyalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12), and C6H4R6 where R6 is chosen from halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkoxy (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • v) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6);
    • vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol; and
    • vii) R5 is H, acyl, alkyl, alkenyl, alkynyl, or cycloalkyl.
  • In one embodiment of the present invention, if the active compound is of formula (II), and X is O, S, CH2, CHF or CF2, R1 is F, and R3 and R3′ are H or F, then R2 cannot be an alkyl, alkoxyalkyl (such as methoxymethyl), aralkyl (such as benzyl or substituted benzyl), aryloxyalkyl (such as phenoxymethyl) or aryl (including but not limited to a phenyl optionally substituted with halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, and C4) or alkoxy (including but not limited to C1, C2, C3, and C4)).
  • The compound of the present invention can be in the form of the isolated β-L- or β-D-configuration, or a mixture thereof, including but not limited to a racemic mixture. In one embodiment, Y is CH2 and both R3 and R3′ groups are hydrogen, forming a d2 nucleoside (i.e., a 2′,3′-dideoxy nucleoside).
  • In one embodiment, the active compound is β-D-N4-p-iodobenzoyl-2′,3′-dideoxy-5-fluorocytidine. Other specific examples of active compounds include β-D-N4-p-fluoro-benzoyl-2′,3′-dideoxy-5-fluorocytidine, β-D-N4-p-chlorobenzoyl-2′,3′-dideoxy-5-fluoro-cytidine, β-D-N4-p-bromobenzoyl-2′,3′-dideoxy-5-fluorocytidine, β-D-N4-p-ethylbenzoyl-2′,3′-dideoxy-5-fluorocytidine, and β-D-N4-p-t-butylbenzoyl-2′,3′-dideoxy-5-fluoro-cytidine.
  • In another embodiment, the active compound is β-D-N4-p-bromobenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine. Other specific examples of active compounds include β-D-N4-p-fluorobenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, β-D-N4-p-chlorobenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, β-D-N4-p-iodobenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, β-D-N4-p-ethylbenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and β-D-N4-p-t-butylbenzoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine.
  • In addition, the 2′,3′-dideoxy-N4-acyl-cytosinenucleosides and 2′,3′-didehydro-2′,3′-dideoxy-N4-acyl-cytosinenucleosides are inhibitors of HBV. Therefore, these compounds can also be used to treat patients that are co-infected with both HIV and HBV.
  • The present invention provides a compound, method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • The present invention provides a compound, method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • The present invention provides a compound, method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • The present invention provides a compound, method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • In another aspect, there is provided a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient for the treatment of a host infected with HIV or HBV.
  • In still another aspect, there is provided a compound, method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • In still another aspect, there is provided a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a non-limiting example of the synthesis of active compounds of the present invention, and in particular, the synthesis of β-D-N4-acyl-2′,3′-dideoxy-5-fluorocytidine and β-D-N4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine nucleosides.
  • FIG. 2 is a graphic representation of the anti-HBV activity of selected N4-acyl-substituted β-D-2′,3′-dideoxy- and β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine analogues.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • It has been found that N4-acyl-cytosine nucleosides, and in particular, N4-acyl-2′,3′-dideoxy-5-fluorocytidine and N4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of a host, and in particular, a human, infected with HIV and/or HBV, is provided that includes administering an effective amount of an N4-acyl-cytosine nucleosides.
  • The present invention also provides a method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • The present invention provides a method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • The present invention provides a method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • The present invention provides a method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • In another aspect, there is provided a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient.
  • In still another aspect, there is provided a method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • In still another aspect, there is provided a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
    • I. Active Compound
  • In one embodiment of the invention, the active compound is of formula (I) or (II):
  • Figure US20120202766A1-20120809-C00002
  • or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O, S, NR5, CH2, CHF or CF2;
    • ii) Y is CH2, CHF or CF2;
    • iii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), CN, CF3, N3, NO2, aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12) and acyl (including but not limited to C2, C3, C4, C5, and C6);
    • iv) R2 is chosen from alkyl (including but not limited to C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), alkenyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), alkynyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), hydroxyalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10 C11, and C12), and C6H4R6 where R6 is chosen from halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkoxy (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • v) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6);
    • vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol; and
    • vii) R5 is H, acyl, alkyl, alkenyl, alkynyl, or cycloalkyl.
  • The compound of the present invention can be in the form of the β-L- or β-D-configuration, or a racemic mixture.
  • In one embodiment of the present invention, if the active compound is of formula (II), and X is O, S, CH2, CHF or CF2, R1 is F, and R3 and R3′ are H or F, then R2 cannot be an alkyl, alkoxyalkyl (such as methoxymethyl), aralkyl (such as benzyl or substituted benzyl), aryloxyalkyl (such as phenoxymethyl) or aryl (including but not limited to a phenyl optionally substituted with halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, and C4) or alkoxy (including but not limited to C1, C2, C3, and C4)).
  • In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) Y is CH2, CHF or CF2;
    • iii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), CN, CF3, N3, NO2, aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12) and acyl (including but not limited to C2, C3, C4, C5, and C6);
    • iv) R2 is chosen from alkyl (including but not limited to C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), alkenyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), alkynyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, and C22), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), hydroxyalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12), and C6H4R6 where R6 is chosen from halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkoxy (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • v) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10, or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more subtituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) Y is CH2, CHF or CF2;
    • iii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), CN, CF3, N3, or NO2;
    • iv) R2 is chosen from cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12), and C6H4R6 where R6 is chosen from halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkoxy (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • v) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) Y is CH2, CHF or CF2;
    • iii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), CN, CF3, N3, or NO2;
    • iv) R2 is chosen from cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12);
    • v) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) Y is CH2, CHF or CF2;
    • iii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), CN, CF3, N3, or NO2;
    • iv) R2 is C6H4R6 where R6 is chosen from CN, CF3, N3, NO2, haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • v) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) Y is CH2, CHF or CF2;
    • iii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), CN, CF3, N3, or NO2;
    • iv) R2 is C6H4R6 where R6 is chosen from halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkoxy (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • v) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol; and.
  • In a particular sub-embodiment of the present invention, the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), CN, CF3, N3, NO2, aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12) and acyl (including but not limited to C2, C3, C4, C5, and C6);
    • iii) R2 is chosen from cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12), and C6H4R6 where R6 is chosen from halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkoxy (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • iv) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • v) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • In a particular sub-embodiment of the present invention, the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including, but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), CN, CF3, N3, and NO2;
    • iii) R2 is chosen from cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12);
    • iv) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • v) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • In a particular sub-embodiment of the present invention, the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), CN, CF3, N3, NO2, aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12) and acyl (including but not limited to C2, C3, C4, C5, and C6);
    • iii) R2 is C6H4R6 where R6 is chosen from halogen ((F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but, not limited to C1, C2, C3, C4, C5, and C6), alkoxy (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • iv) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • v) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • In a particular sub-embodiment of the present invention, the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein
    • i) X is O;
    • ii) R1 is chosen from hydrogen, halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), CN, CF3, N3, NO2, aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, C10, C11, and C12) and acyl (including but not limited to C2, C3, C4, C5, and C6);
    • iii) R2 is C6H4R6 where R6 is chosen from CN, CF3, N3, NO2, haloalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10);
    • iv) R3 and R3′ are chosen independently from H, halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and
    • v) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C1, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • In one embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the ortho position.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ ate independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I) in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Br in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with I in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with F in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Cl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with NO2 in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with methyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with ethyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-propyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-butyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with isopentyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with neopentyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CN in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CF3 in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with N3 in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkoxy in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkenyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkynyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aryl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with furanyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with naphthyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzoyl in the ortho position.
  • In one embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the meta position.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ independently independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I) in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Br in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with I in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with F in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Cl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with NO2 in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with methyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with ethyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-propyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula, its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-butyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with isopentyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with neopentyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CN in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CF3 in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with N3 in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkoxy in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkenyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkynyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aryl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with furanyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with naphthyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzoyl in the meta position.
  • In one embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the para position.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I) in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Br in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with I in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with F in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Cl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with NO2 in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with methyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with ethyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-propyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-butyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with isopentyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with neopentyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CN in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CF3 in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with N3 in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkoxy in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkenyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkynyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aryl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with furanyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with naphthyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzoyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4-dihalo.
  • n yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,6-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,5-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,5-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,5-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,6-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5,6-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4,5-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5-tetrahalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentahalo.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3-dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4-dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5-dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,6-dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • iv) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4-dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,5-dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its Pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,5-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,5-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,6-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5,6-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4,5-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5-tetraalkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentaalkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3-di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4-di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5-di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,6-di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4-di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,5-di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,5-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,5-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,6-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5,6-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4,5-tri-NO2.
  • In one embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the ortho position.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I) in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Br in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with I in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with F in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Cl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with NO2 in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with methyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with ethyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-propyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-butyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with isopentyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with neopentyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CN in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CF3 in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with N3 in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkoxy in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkenyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkynyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aryl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with furanyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with naphthyl in the ortho position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzoyl in the ortho position.
  • In one embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the meta position.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I) in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Br in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with I in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with F in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Cl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with NO2 in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with methyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with ethyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-propyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-butyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with isopentyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with neopentyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CN in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CF3 in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with N3 in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkoxy in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkenyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkynyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aryl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with furanyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with naphthyl in the meta position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzoyl in the meta position.
  • In one embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the para position.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine pr hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with halogen (F, Cl, Br, I) in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Br in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with I in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with F in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with Cl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with NO2 in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with methyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with ethyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-propyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-butyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with isopentyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with neopentyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (H), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CN in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with CF3 in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with N3 in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkoxy in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkenyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with alkynyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl, moiety optionally substituted with aryl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with furanyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with naphthyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with benzoyl in the para position.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,6-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,5-dihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,5-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,5-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,6-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5,6-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4,5-trihalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5-tetrahalo.
  • In yet another embodiment of the present invention, the active compound is of formula (H), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentahalo.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3-dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4- dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5- dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
  • iv) R2 is a phenyl moiety optionally substituted with 2,6- dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4- dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,5- dialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,5-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl, moiety optionally substituted with 2,4,5-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,6-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5,6-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4,5-trialkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5-tetraalkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentaalkyl.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3-di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4- di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5- di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,6- di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4- di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,5- di-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,4-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,3,5-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and d
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,5-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,4,6-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 2,5,6-tri-NO2.
  • In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a phenyl moiety optionally substituted with 3,4,5-tri-NO2.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2-position.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 3-position or the 4-position.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a benzothiophenyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the benzene ring.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a benzothiophenyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the thienyl ring.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a cyclohexyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3-position.
  • In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O; Y is CH2;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a cyclohexyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4-position.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3 position.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4-position.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a benzothiophenyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the benzene ring.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a benzothiophenyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the thienyl ring.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a cyclohexyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3 position.
  • In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
    • i) X is O;
    • ii) R1 is fluorine or hydrogen;
    • iii) R3 and R3′ are independently hydrogen or fluorine; R4 is hydrogen; and
    • iv) R2 is a cyclohexyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4 position.
  • In one preferred embodiment, the active compound is β-D-2′,3′-dideoxy-5-fluoro-N4-(4-iodobenzoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00003
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In another preferred embodiment, the active compound is β-D-2′,3′-dideoxy-5-fluoro-N4-(4-fluorobenzoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00004
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-N4-(4-chlorobenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00005
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-N4-(4-bromobenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00006
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In another preferred embodiment, the active compound is β-D-2′,3′-dideoxy-5-fluoro-N4-(3-fluorobenzoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00007
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-N4-(3-chlorobenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00008
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-N4-(3-bromobenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00009
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In another preferred embodiment, the active compound is β-D-2′,3′-dideoxy-5-fluoro-N4-(4-nitrobenzoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00010
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-2′,3′-dideoxy-5-fluoro-N4-p-toluoylcytidine of the structure:
  • Figure US20120202766A1-20120809-C00011
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-2′,3′-dideoxy-5-fluoro-N4-(m-toluoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00012
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In another preferred embodiment, the active compound is β-D-2′,3′-dideoxy-N4-(4-ethylbenzoyl)-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00013
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-2′,3′-dideoxy-5-fluoro-N4-(4-propylbenzoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00014
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-N4-(4-tert-butylbenzoyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00015
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-2′,3′-dideoxy-5-fluoro-N4-(2-thiophenecarbonyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00016
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-N4-(benzo-[b]-thiophene-2-carbonyl)-2′3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00017
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In another preferred embodiment, the active compound is β-D-N4-(cyclohexane-carbonyl)-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00018
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N4-(4-iodobenzoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00019
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N4-(4-fluorobenzoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00020
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In another preferred embodiment, the active compound is β-D-N4-(4-chlorobenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00021
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-N4-(4-bromobenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00022
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-N4-p-anisoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00023
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N4-(3-nitrobenzoyl)cytidine of the structure:
  • Figure US20120202766A1-20120809-C00024
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N4-p-toluoylcytidine of the structure:
  • Figure US20120202766A1-20120809-C00025
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In another preferred embodiment, the active compound is β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-N4-m-toluoylcytidine of the structure:
  • Figure US20120202766A1-20120809-C00026
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is β-D-N4-(4-t-butylbenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00027
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In still another preferred embodiment, the active compound is β-D-N4-cyclopentanecarbonyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00028
  • or a pharmaceutically acceptable salt or prodrug thereof.
  • In one preferred embodiment, the active compound is (cyclohexanecarbonyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine of the structure:
  • Figure US20120202766A1-20120809-C00029
  • or a pharmaceutically acceptable salt or prodrug thereof.
    • II. Stereoisomerism and Polymorphism
  • The compounds of the present invention have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers or enantiomers, with all isomeric forms being included in the present invention. Some compounds may exhibit polymorphism. The present invention encompasses racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein. The optically active forms can be prepared by, for example, resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution.
  • Examples of methods to obtain optically active materials include at least the following.
      • i) physical separation of crystals: a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist, i.e., the material is a conglomerate, and the crystals are visually distinct;
      • ii) simultaneous crystallization: a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state;
      • iii) enzymatic resolutions: a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme;
      • iv) enzymatic asymmetric synthesis: a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer;
      • v) chemical asymmetric synthesis: a synthetic technique whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e., chirality) in the product, which may be achieved using chiral catalysts or chiral auxiliaries;
      • vi) diastereomer separations: a technique whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the desired enantiomer;
      • vii) first- and second-order asymmetric transformations: a technique whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomer;
      • viii) kinetic resolutions: this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;
      • ix) enantiospecific synthesis from non-racemic precursors: a synthetic technique whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;
      • x) chiral liquid chromatography: a technique whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase (including but not limited to via chiral HPLC). The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;
      • xi) chiral gas chromatography: a technique whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase;
      • xii) extraction with chiral solvents: a technique whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent;
      • xiii) transport across chiral membranes: a technique whereby a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through.
  • Chiral chromatography, including but not limited to simulated moving bed chromatography, is used in one embodiment. A wide variety of chiral stationary phases are commercially available.
    • III. Definitions
  • The term “independently” is used herein to indicate that the variable, which is independently applied, varies independently from application to application. Thus, in a compound such as R″XYR″, wherein R″ is “independently carbon or nitrogen,” both R″ can be carbon, both R″ can be nitrogen, or one R″ can be carbon and the other R″ nitrogen.
  • As used herein, the term “substantially free of” or “substantially in the absence of refers to a nucleoside composition that includes at least 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside. In a preferred embodiment, in the methods and compounds of this invention, the compounds are substantially free of enantiomers.
  • Similarly, the term “isolated” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the nucleoside, the remainder comprising other chemical species or enantiomers.
  • The term “alkyl,” as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon. The term includes both substituted and unsubstituted alkyl groups. The alkyl group may be optionally substituted with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to but limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Specifically included are CF3 and CH2CF3
  • In the text, whenever the term C(alkyl range) is used, the term independently includes each member of that class as if specifically and separately set out. As a nonlimiting example, the term “C1-22” independently represents each species that falls within the scope. Alkyl groups include, but are not limited to the radicals of methane, ethane, propane, cyclopropane, 2-methylpropane(isobutane), n-butane, 2,2-dimethylpropane(neopentane), cytobutane, 1,1 dimethylcyclopropane, 2-methylbutane, trans-1,2-dimethylcyclopropane, ethylcyclopropane, n-pentane, methylcyclobutane, cis-1,2-dimethylcyclopropane, spiropentane, cyclopentane, 2,2-dimethylbutane, 1,1,2-trimethylcyclopropane, 2,3-dimethylbutane, 2-methylpentane, 3-methylpentane, 1,2,3-trimethylcyclopropane, n-hexane, ethylcyclobutane, methylcyclopentane, 2,2dimethylpentane, 2,4-dimethylpentane, cyclohexane, 2,2,3-trimethylbutane, 3,3-dimethylpentane, 1,1-dimethylcyclopentane, 2,3-dimethylpentane, 2-methylhexane, trans-1,3-dimethylcyclopentane, cis-1,3-dimethylcyclopentane, 3-methylhexane, trans-1,2-dimethylcyclopentane, 3-ethylpentane, quadricyclane(quadricyclo[2,2,1,02.6,03.5]heptane), n-heptane, 2,2,4-trimethylpentane, cis-1,2-dimethylcyclopentane, methylcyclohexane, ethylcyclopentane, 1,1,3-trimethylcyclopentane, 2,2-dimethylhexane, 2,5-dimethylhexane, 1,trans-2,cis-4trimethylcyclopentane, 2,4-dimethylhexane, 2,2,3-trimethylpentane, 1,trans-2,cis-3-trimethylcyclopentane, 3,3-dimethylhexane, 2,3,4-trimethylpentane, 1,1,2-trimethylcyclopentane, 2,3,3-trimethylpentane, 2,3-dimethylhexane, 3-ethyl-2-methylpentane, 1,cis-2,trans-4-trimethylcyclopentane, 1,cis-2,trans-3trimethylcyclopentane, 2-methylheptane, 4-methylheptane, 3,4-dimethylhexane, 1,cis-2,cis-4trimethylcyclopentane, 3-ethyl-3-methylpentane, 3-ethylhexane, 3-methylheptane, cylotheptane(suberane), trans-1,4-dimethylcyclohexane, 1,1-dimethylcyclohexane, cis-1,3-dimethylcychohexane, trans-1-ethyl-3-methylcyclopentane, trans-1-ethyl-2-methylcyclopentane, cis-1-ethyl-3-methylcyclopentane, 1-ethyl-1-methylcyclopentane, 2,2,4,4-tetramethylpentane, 1,cis-2-cis-3-trimethylcyclopentane, trans-1,2-dimethylcyclohexane, 2,2,5-trimethylhexane, trans-1,3-dimethylcyclohexane, n-octane, isopropylcyclopentane, 2,2,4-trimethylhexane, cis-1-ethyl-2-methylcyclopentane, cis-1,2-dimethylcyclohexane, 2,4,4-trimethylhexane, n-propylcyclopentane, 2,3,5-trimethylhexane, ethylcyclohexane, 2,2-dimethylheptane, 2,2,3,4-tetramethylpentane, 2,4-dimethylheptane, methylcycloheptane, 2,2,3-trimethylhexane, 4-ethyl-2-methylhexane, 3-ethyl-2.2-dimethylpentane, 4,4-dimethylheptane, 2,6-dimethylheptane, 2,5-dimethylheptane, 3,5-dimethylheptane, bicyclo[4.2.0]octane, cis-bicyclo[3.3.0]octane, 2,4-dimethyl-3-ethylpentane, 1,1,3-trimethylcyclohexane, 3,3-dimethylheptane, 2,2,5,5-tetramethylhexane, 2,3,3-trimethylhexane, 3-ethyl-2-methylhexane, trans-1,3,5-trimethylcyclohexane, 2,3,4-trimethylhexane, cis-1,3,5-trimethylcyclohexane, trans-1,2,4-trimethylcyclohexane, 2,2,3,3-tetramethylpentane, 4-ethyl-3-methylhexane, 3,3,4-trimethylhexane, 2,3-dimethylheptane, 3,4-dimethylheptane, 3-ethyl-3-methylhexane, 4-ethylheptane, 2,3,3,4-tetramethylpentane, 2,3-dimethyl-3-ethylpentane, trans-1,2,3-trimethylcyclohexane, 1-isopropyl-e-methylcyclopentane(pulegan), 4-methyloctane, 1-sopropyl-2-methylcyclopentane, 3-ethylheptane, 2-methyloctane, cis-1,2,3-trimethylcyclohexane, 3-methyloctane, 2,4,6-trimethylheptane, cis-1,2,4-trimethylcyclohexane, 3,3-diethylpentane, 2,2-dimethyl-4-ethylhexane, 2,2,4-trimethylheptane, 2,2,4,5-tetramethylhexane, 2,2,5-trimethylheptane, 2,2,6-trimethylheptane, 2,2,3,5-tetramethylhexane, nopinane(7,7-dimethylbicyclo[3.1.1]heptane), trans-1-ethyl-r-methylcyclohexane, cycloctane, 1-ethyl-2-methylcyclohexane, n-nonane, 1,3,3-trimethylbicyclo[2.2.1]heptane(fenchane), trans-1-ethyl-4-methylcyclohexane, cis-1,1,3,5-tetramethylcyclohexane, cis-1-ethyl-4-methylcyclohexane, 2,5,5-trimethylheptane, 2,4,4-trimethylheptane, 2,3,3,5-tetramethylhexane, 2,2,4,4-tetramethylhexane, isopropylcyclohexane, 1,1,2,2-tetramethylcyclohexane, 2,2,3,4-tetramethylhexane, 2,2-dimethyloctane; 3-ethyl-2,2,4-trimethylpentane, 3,3,5-trimethylheptane, 2,3,5-trimethylheptane, 2,4-dimethyloctane, d,1-cis-1-ethyl-3-methylcyclohexane, d,1-2,5-dimethyloctane, 1,1,3,5-tetramethylcyclohexane, n-butylcyclopentane, n-propylcyclohexane, 2,3,5-trimethylheptane, 2,5-dimethyl-3-ethylhexane, 2,4,5-trimethylheptane, 2,4-dimethyl-3-isopropylpentane, 2,2,3-trimethylheptane, 2,4-dimethyl-4-ethylhexane, 2,2-dimethyl-3-ethylhexane, 2,2,3,4,4-pentamethylpentane, 1,1,3,4-tetramethylcyclohexane, 5-ethyl-2-methylheptane, 2,7-dimethyloctane, 3,6-dimethyloctane, 3,5-dimethyloctane, 4-isopropylheptane, 2,3,3-trimethylheptane, 4-ethyl-2-methylheptane, 2,6-dimethyloctane, 2,2,3,3-tetramethylhexane, trans-1-isopropyl-4-methylcyclohexane(p-menthane), 4,4-dimethyloctane, 2,3,4,5-tetramethylhexane, 5-ethyl-e-methylheptane, 3,3-dimethyloctne, 4,5-dimethyloctane, 3,4-diethylhexane, 4-propylheptane, 1,1,4-trimethylcycloheptane(eucarvane), trans-1,2,3,5-tetramethylcyclohexane, 2,3,4,4-tetramethylhexane, 2,3,4-trimethylheptane, 3-isopropyl-2-methylhexane, 2,2,7-trimethylbicyclo[2.2.1]heptane(α-frenchane), 3-methylheptane, 2,4-dimethyl-3-ethylhexane, 3,4,4-trimethylheptane, 3,3,4-trimethylheptane, 3,4,5-trimethylheptane, 2,3-dimemthyl-4-ethylhexane, 1-methyl-e-propylcyclohexane, 2,3-dimethyloctane, d,1-pinane, 2,3,3,4-tetramethylhexane, 3,3-dimethyl-4-ethylhexane, 5-methylnonane, 4-methylnonane, 3-ethyl-2-methylheptane, 3,4-dimethyloctane, d-α-pinane, d,1-1-isopropyl-3-methylcyclohexane(d,1-m-menthane), 2,2,3,3,4-pentamethylpentane, trans-1,2,4,5-tetramethylcyclohexane, 3,3-diethylhexane, 2-methylnonane, d-1-isopropyl-3-methylcyclohexane(d-m-menthane), 3-ethyl-4-methylheptane, 4-ethyl-3-methylheptane, 4-ethyl-4-methylheptane, 1-β-pinane, 3-methylnonane, 3-ethyloctane, 4-ethyloctane, 3-ethyl-2,2,3-trimethylpentane, 1-1-isopropyl-3 -methylcyclohexane(1-m-menthane)cis-1-isopropyl-4-methylcyclohexane(cis-p-menthane), cis-1,2,3,5-tetramethylcyclohexane, 2,3-dimethyl-3-ethylhexane, 1-isopropyl-4-methylcyclohexane(p-menthane), 3,4-dimethyl-3-ethylhexane, 3,3,4,4-tetramethylhexane, cyclononane, 1-isopropyl-2-methylcyclohexane(o-menthane), cis-1,2,4,5-tetramethylcyclohexane, 1-methyl-1-propylcyclohexane, n-decane, 1-methyl-4-propylcyclohexane, 1-methyl-2-propylcyclohexane, n-pentrylcyclopentane, n-butylcyclohexane, trans-decahydronaphthalene (trans-decalin), isoamylcyclohexane, cis-decahydronaphthalene (cis-decalin), n-undecane(n-hendecane), cyclodecane, n-pentylcyclohexane, n-hexylcyclopentane, 9-methyl-trans-decahydronaphthalene, 1,10-dimethyl-trans-decahydronaphthalene, 9-methyl-cis-decahydronaphthalene, n-dodecane, 1,10-dimethyl-cis-decahydronaphthalene, n-hexycyclohexane, n-heptylcyclopentane, 9-ethyl-trans-decahydronaphthalene, 9-ethyl-cis-decahydronaphthalene, 1-methyl-trans-decahydronaphthalene, n-tridecane, bicyclohexyl, n-octylcyclopentane, n-heptylcyclohexane, n-tetradecane, n-nonylcyclopentane, n-octylcyclohexane, n-pentadecane, n-decyclopentane, n-nonylcyclohexane, n-undecylcyclopentane(n-hendecylcyclopentane), n-decylcyclohexane, 2-methylheptadecane, n-dodecylcyclopentane, n-undecylcyclohexane(n-hendecylcyclohexane), n-tridecylcyclopentane, n-dodecylcyclohexane, n-tetradecylcyclopentane, pentadecycicyclopentane, n-hexadecane(cetane), tridecylcyclohexane, hexadecicyclopentane, n-heptadecane, tetradecylcyclohexane, heptadecylcyclopentane, n-octadecane, pentadecylcyclohexane, octadecylcyclopentane, n-nonadecane, hexadecylcyclohexane, nonadecylcyclopentane, n-eicosane, heptadecylcyclohexane, eicosylcyclopentane, n-heneicosane, octadecylcyclohexane, heneicosylcyclopentane, n-docosane, docosylcyclopentane, nonadecylcyclohexane, n-tricosane, eicosylcyclohexane, tricosylcyclopentane, n-tetracosane, tetracosylcyclopentane, heneicosylcyclohexane, n-pentacosane, pentacosylcyclopentane, docosylcyclohexane, hexacosylcyclopentane, notricyclene(tricyclo[2.2.1.02.6]heptane), n-hexacosane, cyclohexadecane, tricosylcyclohexane, heptacosylcyclopentane, n-heptacosane, tetracosylcyclohexane, cyclopentadecane, octacosylcyclopentane, n-octacosane, pentacosylcyclohexane, nonacosylcyclopentane, n-nonacosane, hexacosylcyclohexane, triacontylcyclopentane, d,1-isobornane(2,2,3-trimethylbicyclo[2.2.2]heptane), n-triacontane, heptacosylcyclohexane, hentriacontylcyclopentane, n-hentriacontane, octacosylcyclohexane, dotriacontylcyclopentane, n-dotriacontane(bicetyl), noncosylcyclohexane, tritriacontylcyclopentane, tritriacontane, triacontylcyclohexane, tetratriacontylcyclopentane, tetratriacontane, 28-methylnonacosane, hentriacontylcyclohexane, pentatriacontylcyclopentane, pentatriacontane, dotriacontylcyclohexane, hexatriacontylcyclopentane, hexatriacontane, tritriacontylcyclohexane, heptatriacontane, tetratriacontylcyclohexane, octatriacontane, pentatriacontylcyclohexane, nonatriacontane, hexatriacontylcyclohexane, tetracontane, norbomane(bicyclo[2.2.1]heptane], 2,2,3,3-tetramethylbutane, bornane(camphane), and adamantane. It is understood to those of ordinary skill in the art that the relevant alkyl radical is named by replacing the suffix “-ane” with the suffix “-yl”.
  • The term “alkenyl” refers to an unsaturated, hydrocarbon radical, linear or branched, in so much as it contains one or more double bonds. The alkenyl group disclosed herein can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Non-limiting examples of alkenyl groups include methylene, ethylene, methylethylene, isopropylidene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3-propane-diyl, 1,2-propane-diyl, 1,3-butane-diyl, and 1,4-butane-diyl.
  • The term “alkynyl” refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds. The alkynyl group may be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to hydroxyl, halo (F, Cl, Br, I), perfluoro alkyl including but not limited to trifluoromethyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, acyl, amido, carboxamido, carboxylate, thiol, alkylthio, azido, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3-methylbutyn-1-yl, hexyn-1-yl, hexyn-2-yl, and hexyn-3-yl, 3,3-dimethylbutyn-1-yl radicals.
  • The term “alkylamino” or “arylamino” refers to an amino group that has one or two alkyl or aryl substituents, respectively.
  • The term “protected” as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
  • The term “aryl”, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. Non-limiting examples of aryl include phenyl, biphenyl, or naphthyl, or the following aromatic group that remains after the removal of a hydrogen from the aromatic ring: benzene, toluene, ethylbenzene, 1,4-xylene, 1,3-xylene, 1,2-xylene, isopropylbenzene(cumene), n-propylbenzene, 1-ethyl-3-methylbenzene(m-ethyltoluene), 1-ethyl-4-methylbenzene(p-ethyltoluene), 1,3,5-trimethylbenzene(mesitylene), 1-ethyl-2-methylbenzene(o-ethyltoluene), tert-butylbenzene, 1,2,4-trimethylbenzene(pseudodocumene), isobutylbenzene, sec-butylbenzene, 3-isopropyl-methylbenzene(3-isopropyltoluene; m-cymene), 1,2,3-trimethylbenzene(hemimellitene), trans-propenylbenzene, indane, 4-isopropyl-1-methylbenzene(4-isopropyltoluene; 4-cymene), 2-isopropyl-methylbenzene(2-isopropyltoluene; 2-cymene), 1,3-diethbenzene, 1 methyl-3-proplybenzene(m-propyltoluene), indene, n-butylbenzene, 1-methyl-4-propylbenzene(p-propyltoluene), 1,2-diethylbenzene, 1,4-diethylbenzene, 1,3-dimethyl-5-ethylbenzene, 1-methyl-2-propylbenzene(o-propyltoluene), 2,2-dimethyl-1-phenylpropane(neopentylbenzene), 1,4-dimethyl-2-ethylbenzene, 2-methylindane, 3-methyl-2-phenylbutane, 1-methylindane, 1,3-dimethyl-4-ethylbenzene, 3-tert-butyl-menthylbenzene, (3-tert-butyltoluene), 1,2-dimethyl-4-ethylbenzene, 1,3-dimethyl-2-ethylbenzene, 3-phenylpentane, 1-ethyl-3-isopropylbenzene, 2-methyl-2-phenylbutane, 4-tert-butyl1-methylbenzene(4-tert-butyltoluene), 1-ethyl-2-isopropylbenzene, 2-phenylpentane, 1,2-dimethyl-3-ethybenzene, 3-sec-butyl-1-methylbenzene, (3-sec-butylotoluene), 3-isobutyl-1-methylbenzene, (3-isobutyltoluene), d-2-methyl-1-phenylbutane, 1,3-dimethyl-5-isopropyl-benzene, 2-phenyl-cis-2-butene, 4-isobutyl-methylblenzene(p-isobutyltoluene), 2-sec-butyl-1-methylbenzene(2-sec-butyltoluene), 2-isobutyl-1-methylblenzene(o-isobutyltoluene), 1,4-dimethyl-2-isopropyl-benzene, 1-ethyl-4-isopropylbenzene, d,1-2-methyl-1-phenylbutane, 1,2,3,5-tetramethylbenzene(isodurene), 3-methyl-1-phenylbutane(isopentylbenzene), 1,3-dimethyl-2-isopropylbenzene, 1,3-dimethyl-4-isopropylbenzene), 3-methylindene, 4-sec-butyl-1-methylbenzene(p-sec-butyltoluene), 2-tent-butyl-1-methylbenzene(2-tert-butyltoluene), 3,5-diethyl-1-methylbenzene(3,5-diethyltoluene), 2-butyl-1-methylbenzene (2 butyltoluene), 1-ethyl-3-propylbenzene, 1,2-dimethyl-4-isopropylbenzene, 1,2-dimethyl-3-isopropylbenzene, 1-ethyl-2-propylbenzene, 1,3-di-isopropyllbenzene, 1,2-diethyl-4-methylbenzene, 1,2-di-isopropylbenzene, 1,4-dimethyl-2-proplybenzene, 1,2,3,4-tetramethylbenzene(prehnitene), 1-ethyl-4-propylbenzene, 3-butyl-1-methlybenzene (m-butyltoluene), 2,4-diethyl-1-methylbenzene (2,4-diethyltoluene), n-pentylbenzene, 3-methyl-3-phenylpentane, 1,3-dimethyl-5-tert-butylbenzene, 1,3-dimethyl-4-propylbenzene, 1,2-diethyl-3-methylbenzene, 4-butyl-1-methylbenzene, 4-butyl-1-methylbenzene, 1,2,3,4-tetrahydronaphthalene, 1,3-diethyl-2-propylbenzene, 2,6-diethyl-1-methylbenzene, 1,2-dimethyl-4-propylbenzene, 1,3-dimethyl-5-propylbenzene, 2-methyl-3-phenylpentane, 4-teri-butyl-1,3-dimethylbenzene, 1,4-di-isopropylbenzene, 1,2-dimethyl-3-propylbenzene, 1-tert-butyl-4-ethylbenzene, d,I-3-phenylhexane, 2-ethyly-1,3,5-trimethyl-benzene, 3-ethyly-4-isopropyl-1-methylbenzene, 5-ethyl-1,2,4-trimethylbenzene, 6-ethyl-1-2,4-trimethylbenzene, 2-phenylhexane, 2-methyl-1-phenylpentane, 4-isopropyl-1-propylbenzene, 1,3-dipropylbenzene, 5-ethyl-1,2,3-trimethylbenzene, 1,2,4-triethylbenzene, 1,3,5-triethylbenzene, 2-methyl-1,2,3,4-tetrahydronaphthalene, 1-methyl-1,2,3,4-tetrahydronaphthalene, 4-ethyl-1,2,3-trimethylbenzene, 1,4-dipropylbenzene, 3-methyl-1-phenylpentane, 2-propyl-1,3,5-trimethylbenzene, 1,1-dimethyl-1,2,3,4-tetrahydronaphthalene, 3-tert-butyl-1-isopropylbenzene, 1-methyl-3-pentylbenzene, 4-tert-butyl-1-isopropylbenzene, 2-methyl-2-phenylhexane, 2,4-di-isopropyl-1-methylbenzene, 3-methyl-3-phenylhexane, n-hexylbenzene, 3-phenylheptane, 2,6-di-isopropyl-1-methylbenzene, 5-propyl-1,2,4-trimethylbenzene, 6-methyl-1,2,3,4-tetrahydronaphthalene, 2,2-d imethyl-1,2,3,4-tetrahydronaphthalene, 2-phenylheptane, 5-methyl-1,2,3,4-tetrahydronaphthalene, 2-ethyl-1,2,3,4-tetrahydronaphthalene, cyclohexylbenzene, 1-ethyl-1,2,3,4-tetrahydronaphthalene, 2,5 -dimethyl-1,2,3,4-tetrahydronaphthalene, 2,8-dimethyl-1,2,3,4-tetrahydronaphthalene, 2,7-dimethyl-1,2,3,4-tetrahydronaphthalene, 2,6-dimethyl-1,2,3,4-tetrahydronaphthalene, 1,4-di-sec-butylbenzene, 1,5-dimethyl-1,2,3,4-tetrahydronaphthalene, 3-ethyl-3-phenylhexane, 6-ethyl-1,2,3,4-tetrahydronaphthalene, 2-methyl-1-phenyl-1-butene, 5-ethyl-1,2,3,4-tetrahydronaphthalene, n-heptylbenzene, 1-methylnaphthalene, 5,6-dimethyl-1,2,3,4-tetrahydronaphthalene, 6,7-dimethyl-1,2,3,4-tetrahydronaphthalene, 5,7-dimethyl-1,2,3,4-tetrahydronaphthalene, 2-ethylnaphthalene, 1-7-dimethylnaphthalene, 1,6-dimethylnaphthalene, 1,3-dimethylnaphthalene, n-octylbenzene, 1-allylnaphthalene, 1-isopropylnaphthalene, 1,4-dimethylnaphthalene, 1,1 -diphenyl ethane, 2-isopropylnaphthalene, 2-propylnaphthalene, 1-propylnaphthalene, 1,3,7-trimethylnaphthalene, 1-isopropyl-7-methylnaphthalene, n-nonylbenzene, 2-butylnaphthalene, 2-tert-butylnaphthalene, 1-tert-butylnaphthalene, 1-butyl naphthalene, 4,5-benzindane, n-decylbenzene, 1-pentylnaphthalene, 2-pentylnaphthalene, n-undecylbenzene, 1-hexylnaphthalene, 2-hexylnaphthalene, n-dodecylbenzene, 1-heptylnaphthalene, 2-heptylnaphthalene, tridecylbenzene, 1-octylnaphthalene, 2-octylnaphthalene, 1-nonylnaphthalene, 2-nonylnaphthalene, 1-decylnaphthalene, 1,2,6-trimethylnaphthalene, diphenylmethane, 1,2,3 -trimethylnaphthalene, 1,6,7-trimethylnaphthalene, 2-isopropylazulene, 1,4-dimethyl-7-isopropylazulene, 2,6-dimethylphenanthrene, 1,2,5-trimethylnaphthalene, 1-propylphenanthrene, 5-isopropylazulene, 5-isopropylazulene, 2-propylphenanthrene, 2-methylnaphthalene, 1-ethyl-5-methylnaphthalene, 9-isopropylnaphthalene, 6-isopropylazulene, 2-ethyl-6-methylnaphthalene, 2-isopropyiphenanthrene, 6-isopropyl-1-methylphenanthrene, 2-ethylazulene, 2,5,-dimethylphenanthrene, 1,3,5-trimethylnaphthalene, 3-ethyl-6-methylphenanthrene, 2-methylazulene, 1,3,8-trimethylnaphthalene, 4-methylphenanthrene, 1,4-dimethylphenanthrene, bibenzyl, methylenefluorene, 3,5-dimethylphenanthrene, 1,3-dimethylazulene, 7-methyl-3,4-benzphenanthrene, pentamethylbenzene, 1,2,4-trimethylnaphthalene, 3,3-dimethylstilbene, 1,4,5,74etramethylnaphthalene, 1,2,4,8-tetramethylnaphthalene, 2,9-dimethylphenanthrene, 1,5-dimethylphenanthrene, 2-benzylnaphthalene, 1-benzylnaphthalene, 1-benzylnaphthalene, 1,2-dimethylazulene, 9-propylphenanthrene, 1,7-dimethyl-4-isopropylnaphthalene, 3-methylphenanthrene, 3,4-dimethylphenanthrene, 1-ethylphenanthrene, sym-diphenylacetylene, 9-ethylphenanthrene, 1,4,5-trimethylnaphthalene, 4-methyl fluorene, 1,4,6,7-tretramethylnaphthalene, 1,2,3-trimethylphenanthrene, 1,8-dimethylnaphthalene, 8-methyl-3,4-benzphenanthrene, 2-ethylphenanthrene, 3,4-benzphenanthrene, 1,3,7-trimethylphenanthrene, 4-isopropyl-1-methylphenanthrene, 4,8-dimethylazulene, biphenyl, 2-methyl-3,4-benzphenanthrene, 3-methylpyrene, 1,4,7-trimethylphenanthrene, 1,4-dimethylanthracene, 4,9-dimethyl-1,2-benzanthracene, benzalfluorene, 1,3-dimethylphenanthrene, 1-methyl-3,4-benzphenanthrene, 3-isopropyl-1-methylphenanthrene, 1,2-binaphthyl, 2,3-dimethylphenanthrene, 1-ethyl-2-methylphenanthrene, 1,5-dimethylnaphthalene, 6-methyl-3,4-benzphenanthrene, naphthalene, 1,3,6,8-tetramethylnaphthalene, 1-ethyl-7methylphenanthrene, 9-methylanthracene, 1-isopropyl-7-methylphenanthrene, 6-methylazulene, 1,3-dimethylanthracene, 2,2-dimethylstilbene, 1-methylanthracene, 1,7-dimethylphenanthrene, 1,6-diphenylnaphthalene, 1,6-dimethylphenanthrene, 1,9-dimethylphenanthrene, 9-methylphenanthrene, 1,2,10-trimethylanthracene, 7-ethyl-1-methylphenanthrene, triphenylmethane, 5- isopropylnaphthanthracene, 3,9-dimethyl-1,2-benzanthracene, 5,6-benzindane, 12 -isopropylnaphthanthracene, acenaphthene, 2,7-dimethylnaphthalene, 7-isopropyl-1-methylfluorene, azulene, retene, phenanthrene, 2,7-dimethfylphenanthrene, 2,3,6-trimethfylnaphthalene, 2-phenylnaphthalene, 1,2,3,4-tetrahydroanthracene, 2,3-dimethylnaphthalene, ethyl idenefluorene, 1,7-dimethylfuorene, 1,1-dinaphthylmethane, fluoranthrene, 2,6-dimethylnaphthalene, 2,4-dimethylphenanthrene, fluorene, 4,10-dimethyl-1,2-benzanthracene, 4h-cyclopenta(def)phenanthrene, 1,3,8-trimethylphenanthrene, 11-methylnaphthanthracene, 5-methylchrysene, 1,2,5,6-tetramethylnaphthalene, cyclohept(fg)acenaphthene, 1,2,7-trimethylphenanthrene, 1,10-dimethyl-1,2-dibenzanthracene, 9,10-dimethyl-1,2-benzanthracene, benz(bc)aceanthrylene, 1-methylphenanthrene, 1,6,7-trimethylphenanthrene, 1,1-diacenaphthene, trans-stilbene, 3,4-benzflurorene, 9-isopropylnaphthanthracene, 6-methylnaphthanthracene, 5,8-dimethyl-1,2-bezanthracene, 8-isopropylnaphthanthracene, 1,4,5,8-tetramethylnaphthalene, 12-methylnaphthanthracene, 2-methyl-1,2-benzpyrene, 1,5-dimethylanthracene, 7-methylnaphthanthracene, 3,6-dimethylphenanthrene, 5-methyl-3,4-benzphenanthrene, 1,4-dimethylchrysene, 1,2-dimethylphenanthrene, 8,10-dimethyl-1,2-benzanthracene, 1,2,8-trimethylphenanthrene, 3-methyl-1,2-benzpyrene, 9-methyl-1,2-benzpyrene, 9-phenylfluorene, 2-methylnaphthanthracene, pyrene, 9-methylnaphthanthracene, 4-methylchrysene, trans-trans-1,4-diphenyl-1,3-butadiene, cinnamalfluorene, 5-methylnaphthanthracene, 1,2-benzanthracene, 8-methylnaphthanthracene, 1,1-binaphthyl, di-1-naphthastibene, 6-methylchrysene, 3-methyl naphthanthracene, 2,6-dimethyl-1,2-benzanthracene, cyclopentadienophenanthrene, 10,11-benzfluoranthene, hexamethylbenzene, 3-methylchrysene, cholanthrene, 6-methyl-1,2-benzpyrene, 6,7-dimethyl-1,2-benzanthracene, 1,2-benzpyrene, 5,10-dimethyl-1,2-benzanthracene, 4,5-benzpyrene, 9,10-dimethylanthracene, 10-methylnaphthanthracene, 5,6-dimethyl-1,2-benzanthracene, 2,2-binaphthyl, 1,2-benfluorene, 1,8-dimethylphenanthrene, 8-methyl-1,2-benzpyrene, bifluorenylidene, 1,2,7,8-dibenzanthracene, 4-methylnaphthanthracene, 1,2,3,4-dibenzanthracene, di -2-fluorenylmethane, 2,3-benzfluorene, 5-methyl-1,2-benzpyrene, anthracene, 11,12-benzfluoranthene, 4-methyl-1,2-benzpyrene, 2,8-dimethylchrysene, 2-methylchrysene, 6,12-dimethylehrysene, 1,2-benzphenanthrene, di-2-naphthastilbene, 1-methylchrysene, 2,3,6,7-dibenzphenanthrene, 2,3,5,6-dibenzphenanthrene, 1,2,5,6-dibenzanthracene, perylene, picene, 1,2,3,4,5,6,7,8-tertrabenzanthracene, and coronene. The term aryl includes both substituted and unsubstituted moieties. The aryl group may be optionally substituted with any moiety that does not adversely affect the process, including but not limited to but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Non-limiting examples of substituted aryl include heteroarylamino, N-aryl-N-alkylamino, N-heteroarylamino-N-alkylamino, heteroaralkoxy, arylamino, aralkylamino, arylthio, monoarylamidosulfonyl, arylsulfonamido, diarylamidosulfonyl, monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, hydroxyaralkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl, carboaralkoxy. The terms “alkaryl” or “alkylaryl” refer to an alkyl group with an aryl substituent. The terms “aralkyl” or “arylalkyl” refer to an aryl group with an alkyl substituent.
  • The term “halo,” as used herein, includes chloro, bromo, iodo and fluoro.
  • The term “acyl” refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including but not limited to methoxymethyl, aralkyl including but not limited to benzyl, aryloxyalkyl such as phenoxymethyl, aryl including but not limited to phenyl optionally substituted with halogen (F, Cl, Br, I), alkyl (including but not limited to C1, C2, C3, and C4) or alkoxy (including but not limited to C1, C2, C3, and C4), sulfonate esters such as alkyl or aralkyl sulphonyl including but not limited to methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g., dimethyl-t-butylsilyl) or diphenylmethylsilyl. Aryl groups in the esters optimally comprise a phenyl group. The term “lower acyl” refers to an acyl group in which the non-carbonyl moiety is lower alkyl.
  • The terms “alkoxy” and “alkoxyalkyl” embrace linear or branched oxy-containing radicals having alkyl moieties, such as methoxy radical. The term “alkoxyalkyl” also embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The “alkoxy” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide “haloalkoxy” radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropoxy.
  • The term “alkylamino” denotes “monoalkylamino” and “dialkylamino” containing one or two alkyl radicals, respectively, attached to an amino radical. The terms arylamino denotes “monoarylamino” and “diarylamino” containing one or two aryl radicals, respectively, attached to an amino radical. The term “aralkylamino”, embraces aralkyl radicals attached to an amino radical. The term aralkylamino denotes “monoaralkylamino” and “diaralkylamino” containing one or two aralkyl radicals, respectively, attached to an amino radical. The term aralkylamino further denotes “monoaralkyl monoalkylamino” containing one aralkyl radical and one alkyl radical attached to an amino radical.
  • The term “heteroatom,” as used herein, refers to oxygen, sulfur, nitrogen and phosphorus.
  • The terms “heteroaryl” or “heteroaromatic,” as used herein, refer to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
  • The term “heterocyclic” refers to a nonaromatic cyclic group wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring.
  • Nonlimiting examples of heteroaryl and heterocyclic groups include furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole pyrimidine or pyridazine, and pteridinyl, aziridines, thiazole, isothiazole, 1,2,3-oxadiazole, thiazine, pyridine, pyrazine, piperazine, pyrrolidine, oxaziranes, phenazine, phenothiazine, morpholinyl, pyrazolyl, pyridazinyl, pyrazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, adenine, N6-alkylpurines, N6-benzylpurine, N6-halopurine, N6-vinypurine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, thymine, cytosine, 6-azapyrimidine, 2-mercaptopyrmidine, uracil, N5-alkylpyrimidines, N5-benzylpyrimidines, N5-halopyrimidines, N5-vinylpyrimidine, N5-acetylenic pyrimidine, N5-acyl pyrimidine, N5-hydroxyalkyl purine, and N6-thioalkyl purine, and isoxazolyl. The heteroaromatic group can be optionally substituted as described above for, aryl. The heterocyclic or heteroaromatic group can be optionally substituted with one or more substituent selected from halogen (F, Cl, Br, I), haloalkyl, alkyl, alkoxy, hydroxy, carboxyl derivatives, amido, amino, alkylamino, dialkylamino. The heteroaromatic can be partially or totally hydrogenated as desired. As a nonlimiting example, dihydropyridine can be used in place of pyridine. Functional oxygen and nitrogen groups on the heterocyclic or heteroaryl group can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl. The heterocyclic or heteroaromatic group can be substituted with any moiety that does not adversely affect the reaction, including but not limited to but not limited to those described above for aryl.
  • The term “host,” as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including but not limited to cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds of the present invention. The term host specifically refers to infected cells, cells transfected with all or part of the viral genome and animals, in particular, primates (including but not limited to chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as chimpanzees).
  • The term “pharmaceutically acceptable salt or prodrug” is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a nucleoside compound which, upon administration to a patient, provides the nucleoside compound. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound. The compounds of this invention possess antiviral activity against Flaviviridae, or are metabolized to a compound that exhibits such activity.
  • Prodrugs also include natural or unnatural amino acid esters of the disclosed nucleosides (see, e.g., European Patent Specification No. 99493, the text of which is incorporated by reference, which describes amino acid esters of acyclovir, specifically the glycine and alanine esters which show improved water-solubility compared with acyclovir itself, and U.S. Pat. No. 4,957,924 (Beauchamp), which discloses the valine ester of acyclovir, characterized by side-chain branching adjacent to the α-carbon atom, which showed improved bioavailability after oral administration compared with the alanine and glycine esters). A process for preparing such amino acid esters is disclosed in U.S. Pat. No. 4,957,924 (Beauchamp), the text of which is incorporated by reference. As an alternative to the use of valine itself, a functional equivalent of the amino acid may be used (e.g., an acid halide such as the acid chloride, or an acid anhydride). In such a case, to avoid undesirable side-reactions, it may be is advantageous to use an amino-protected derivative.
    • IV. Nucleotide Salt or Prodrug Formulations
  • In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate and α-glycerophosphate. Suitable inorganic salts may also be formed, including but not limited to, sulfate, nitrate, bicarbonate and carbonate salts.
  • Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid, affording a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be made.
  • Any of the nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside. A number of nucleotide prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide. Examples of substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including but not limited to sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones & N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed nucleosides to achieve a desired effect.
  • The active nucleoside can also be provided as a 5′-phosphoether lipid or a 5′-ether lipid, as disclosed in the following references, which are incorporated by reference: Kucera, L. S., N. Iyer, E. Leake, A. Raben, Modest E. K., D. L. W., and C. Piantadosi, “Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation,” AIDS Res. Hum. Retroviruses, 1990, 6, 491-501; Piantadosi, C., J. Marasco C. J., S. L. Morris-Natschke, K. L. Meyer, F. Gumus, J. R. Surles, K. S. Ishaq, L. S. Kucera, N. Iyer, C. A. Wallen, S. Piantadosi, and E. J. Modest, “Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity,” J. Med. Chem., 1991, 34, 1408-1414; Hosteller, K. Y., D. D. Richman, D. A. Carson, L. M. Stuhmiller, G. M. T. van Wijk, and H. van den Bosch, “Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3′-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3,-deoxythymidine,” Antimicrob. Agents Chemother., 1992, 36, 2025-2029; Hostetler, K. Y., L. M. Stuhmiller, H. B. Lenting, H. van den Bosch, and D. D. Richman, “Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides.” J. Biol. Chem., 1990, 265, 61127.
  • Nonlimiting examples of US patents that disclose suitable lipophilic substituents that can be covalently incorporated into the nucleoside, preferably at the 5′-OH position of the nucleoside or lipophilic preparations, include U.S. Pat. No. 5,149,794 (Yatvin et al.); U.S. Pat. No. 5,194,654 (Hostetler et al.), U.S. Pat. No. 5,223,263 (Hostetler et al.); U.S. Pat. No. 5,256,641 (Yatvin et al.); U.S. Pat. No. 5,411,947 (Hostetler et al.); U.S. Pat. No. 5,463,092 (Hostetler et al.); U.S. Pat. No. 5,543,389 (Yatvin et al.); U.S. Pat. No. 5,543,390 (Yatvin et al.); U.S. Pat. No. 5,543,391 (Yatvin et al.); and U.S. Pat. No. 5,554,728 (Basava et al.), all of which are incorporated by reference. Foreign patent applications that disclose lipophilic substituents that can be attached to nucleosides of the present invention, or lipophilic preparations, include WO 89/02733, WO 90/00555, WO 91/16920, WO 91/18914, WO 93/00910, WO 94/26273, WO 96/15132, EP 0 350 287, EP 93917054.4, and WO 91/19721.
    • V. Combination or Alternation Therapy
  • In another embodiment for the treatment of HIV or HBV infection, the active compound or its prodrug or salt can be administered in combination or alternation with another antiviral agent, such as another active anti-HIV or anti-HBV agent, including but not limited to those of the formulae above, others listed below or known in the art. In general, in combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy, an effective dosage of each agent is administered serially. The dosage will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject; specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
  • Nonlimiting examples of antiviral agents that can be used in combination with the compounds disclosed herein include those in the tables below.
  • Hepatitis B Therapies
    Drug Name Drug Class Company
    Intron A (interferon alfa-2b) interferon Schering-Plough
    Epivir-HBV (lamivudine; 3TC) nucleoside analogue GlaxoSmithKline
    Hepsera (Adefovir Dipivoxi)″ nucleotide analogue Gilead Sciences
    Coviracil (emtricitabine; FTC) nucleoside analogue Triangle Pharmaceuticals
    Entecavir nucleoside analogue Bristol-Myers Squibb
    Clevudine (L-FMAU) nucleoside analogue Triangle Pharmaceuticals
    ACH 126, 443 (L-Fd4C) nucleoside analogue Achillion Pharmaceuticals
    AM 365 nucleoside analogue Amrad
    Amdoxovir (formerly DAPD) nucleoside analogue Triangle Pharmaceuticals
    LdT (telbivudine) nucleoside analogue Idenix
    XTL 001 monoclonal antibody XTL Biopharm
    Theradigm Immune stimulant Epimmune
    Zadaxin (thymosin) Immune stimulant SciClone
    EHT 899 viral protein Enzo Biochem
    HBV DNA vaccine Immune stimulant PowderJect (UK)
    MCC 478 nucleoside analogue Eli Lilly
    valLdC (valtorcitabine) nucleoside analogue Idenix
    ICN 2001 nucleoside analogue ICN
    Fluro L and D nucleosides nucleoside analogue Pharmasset
    Racivir nucleoside analogue Pharmasset
    Robustaflavone nucleoside analogue Advanced Life Sciences
    Penciclovir
    DXG
    HDP-P-acyclovir
    LM-019c
    CS-109
    PS-019
    PS-018
    ara-AMP prodrugs
    HBV/MF59
    Hammerhead ribozymes
    Glycosidase Inhibitors
    Pegylated Interferon
    Human Monoclonal Antibodies
    Famciclovir
  • HIV Therapies: Protease Inhibitors (PIs)
    Brand Pharmaceutical
    Name Generic Name Abbreviation Company
    Invirase ® saquinavir (Hard SQV (HGC) Hoffmann-La Roche
    Gel Cap)
    Fortovase ® saquinavir (Soft SQV (SGC) Hoffmann-La Roche
    Gel Cap)
    Norvir ® ritonavir RTV Abbott Laboratories
    Crixivan ® indinavir IDV Merck & Co.
    Viracept ® nelfinavir NFV Pfizer
    Agenerase ® amprenavir APV GlaxoSmithKline
    Kaletra ® lopinavir + LPV Abbott Laboratories
    ritonavir
    fosamprenavir GlaxoSmithKline
    tipranavir TPV Boehringer Ingelheim
    atazanavir Bristol-Myers Squibb
  • HIV Therapies: Nucleoside/Nucleotide Reverse
    Transcriptase Inhibitors (NRTIs)
    Brand Pharmaceutical
    Name Generic Name Abbreviation Company
    Retrovir ® zidovudine AZT or ZDV GlaxoSmithKline
    Epivir ® lamivudine 3TC GlaxoSmithKline
    Combivir ® zidovudine + AZT + 3TC GlaxoSmithKline
    lamivudine
    Trizivir ® abacavir + ABC + AZT + GlaxoSmithKline
    zidovudine + 3TC
    lamivudine
    Ziagen ® abacavir ABC GlaxoSmithKline
    Hivid ® zalcitabine ddC Hoffmann-La Roche
    Videx ® didanosine: buffered ddI Bristol-Myers
    versions Squibb
    Videx ® EC didanosine: delayed- ddI Bristol-Myers
    release capsules Squibb
    Zerit ® stavudine d4T Bristol-Myers
    Squibb
    Viread ™ tenofovir disoproxil TDF or Gilead Sciences
    fumarate (DF) Bis(POC)
    PMPA
    Coviracil ™ emtricitabine FTC Triangle
    Pharmaceuticals
    amdoxovir DAPD Triangle
    Pharmaceuticals
  • HIV Therapies: Non-Nucleoside Reverse
    Transcriptase Inhibitors (NNRTIs)
    Brand Name Generic Name Abbreviation Pharmaceutical Company
    Viramune ® nevirapine NVP Boehringer Ingelheim
    Rescriptor ® delavirdine DLV Pfizer
    Sustiva ® efavirenz EFV Bristol-Myers Squibb
    (+)-calanolide A Sarawak Medichem
    capravirine CPV Pfizer
    Bristol-Myers Squibb
    Tibotec-Virco Group
    Tibotec-Virco Group
  • HIV Therapies: Other Classes of Drugs
    Pharmaceutical
    Brand Name Generic Name Abbreviation Company
    Viread ™ tenofovir disoproxil TDF or Bis(POC) Gilead Sciences
    fumarate (DF) PMPA
  • Cellular Inhibitors
    Brand Pharmaceutical
    Name Generic Name Abbreviation Company
    Droxia ® hydroxyurea HU Bristol-Myers Squibb
  • Entry Inhibitors (including Fusion Inhibitors)
    Brand Generic Pharmaceutical
    Name Name Abbreviation Company
    Fuzeon ™ enfuvirtide Trimeris
    Trimeris
    AnorMED, Inc.
    Progenics Pharmaceuticals
  • HIV Therapies: Immune-Based Therapies
    Brand Pharmaceutical
    Name Generic Name Abbreviation Company
    Proleukin ® aldesleukin, or IL-2 Chiron Corporation
    Interleukin-2
    Remune ® HIV-1 The Immune
    Immunogen, or Response
    Salk vaccine Corporation
    HollisEden
    Pharmaceuticals
  • HIV Therapies: Treatments for Side Effects
    Pharmaceutical
    Brand Name Generic Name Side Effect Company
    Procrit ® epoetin alfa Anemia Ortho Biotech
    (erythropoietin)
    Serostim ® somatropin, or Lipodystrophy Serono
    human growth Laboratories
    hormone
  • In one embodiment, the compounds of the invention may be employed together with at least one other antiviral agent chosen from reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors and polymerase inhibitors.
  • In addition, compounds according to the present invention can be administered in combination or alternation with one or more anti-retrovirus, anti-HBV, anti-HCV or anti-herpetic agent or interferon, anti-cancer or antibacterial agents, including but not limited to other compounds of the present invention. Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents according to the present invention by reducing the metabolism, catabolism or inactivation of other compounds and as such, are co-administered for this intended effect.
    • VI. Pharmaceutical Compositions
  • Host, including but not limited to humans, infected with a human immunodeficiency virus, a hepatitis virus, or a gene fragment thereof, can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
  • A preferred dose of the compound for an HIV or HBV infection will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day. The effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
  • The compound is conveniently administered in unit any suitable dosage form, including but not limited to but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form. An oral dosage of 50-1000 mg is usually convenient.
  • Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 μM, preferably about 1.0 to 10 μM. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
  • The concentration of active compound in the drug composition will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • A preferred mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, unit dosage forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
  • The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compound(s), sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • The compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories or other antivirals, including but not limited to other nucleoside compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for the adjustment of tonicity, such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
  • In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including but not limited to implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. For example, enterically coated compounds can be used to protect cleavage by stomach acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Suitable materials can also be obtained commercially.
  • Liposomal suspensions (including but not limited to liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (incorporated by reference). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
    • VII. Processes for the Preparation of Active Compounds
  • A method for the facile preparation of N4-acyl-substituted 2′,3′-dideoxy-5-fluorocytidine and 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine nucleosides is also provided. The method includes condensation of a 5′-O-silyl protected 2′,3′-dideoxy-5-fluorocytidine or a 5′-O-silyl protected 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, with either a carboxylic acid chloride, or carboxylic acid anhydride, or a carboxylic acid, followed by desilylation. The other N4-acyl-substituted cytosine nucleosides can be synthesized using the similar approaches.
  • The N4-acyl-substituted 2′,3′-dideoxy-5-fluorocytidine and 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine nucleosides disclosed herein can be prepared as described in detail below, or by other assays known to those skilled in the art.
  • The present invention is further illustrated in the following examples. It will be understood by one of ordinary skill in the art that these examples are in no way limiting and that variations of detail can be made without departing from the spirit and scope of the present invention.
    • EXAMPLES
  • Anhydrous solvents were purchased from Aldrich Chemical Company, Inc. (Milwaukee). Melting points (mp) were determined on an Electrothermal digit melting point apparatus and are uncorrected. 1H and 13C NMR spectra were taken on a Varian Unity Plus 400 spectrometer at room temperature and reported in ppm downfield from internal tetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSY were performed to confirm proton assignments. Signal multiplicities are represented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quadruplet), br (broad), bs (broad singlet), m (multiplet). All J-values are in Hz. Mass spectra were recorded on a JEOL JMS-SX/SX102A/E mass spectrometer. Elemental analyses were performed by Atlantic Microlab Inc. (Norcross, Ga.). Analytic TLC was performed on Whatman LK6F silica gel plates, and preparative TLC on Whatman PK5F silica gel plates. Column chromatography was carried out on Silica Gel (Fisher, S733-1) at atmospheric pressure.
    • Example 1 (S)-(+)-5-Oxo-2-tetrahydrofurancarboxylic acid (2)
  • To a mixture of L-glutamic acid (1, 25 g, 170 mmol) in water (67 mL) and conc. HCl (35 mL) at 0° C. with stirring was added a solution of NaNO2 (17.5 g, 253.6 mmol) in water (37.5 mL) over a period of 4 h, and then the resulting clear solution was stirred at room temperature overnight. After removal of the solvent by evaporation in vacuo, the residue was treated with EtOAC (80 mL) and filtered. The filtrate was dried over Na2SO4, and concentrated. The residue, after crystallization from EtOAc/benzene/hexane, afforded the title compound 2 as a white crystalline solid (13.12 g, 59%). M.P. 71-73° C.; 1H NMR (400 MHz, CD3OD) δ4.20 (m, 1H, CHO), 1.8-2.3 (m, 4H, CH2CH2).
    • Example 2 (S)-(+)-Dihydro-5-(hydroxymethyl)-2(3H)-furanone (3)
  • To a solution of 2 (10 g, 76.85 mmol) in anhydrous THF (200 mL) at 0° C. was slowly added BH3—SMe2 (2 M solution in THF, 46.1 mL, 92.2 mmol) over a period of 10 min. The reaction solution was stirred at 0° C. for 3 h under nitrogen, followed by the slow addition of anhydrous MeOH (20 mL). After removal of the solvent, the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (95:5) to give the title compound 3 as a colorless oil (8.41 g, 94%). 1H NMR (CDCl3) δ4.66-4.65 (m, 1H, H-5), 3.95-3.91 (m, 1H, CH2OH), 3.72-3.65 (m, 1H, CH2OH), 2.65-2.57 (m, 2H, H-3), 2.30-2.17 (m, 3H, H-4, OH).
    • Example 3 (S)-5-[(tert-Butyldiphenylsilyl)hydroxymethyl]-dihydro-2(3H)-furanone (4)
  • To a solution of 3 (7.0 g, 60 mmol) and imidazole (9.19 g, 135 mmol) in anhydrous DMF (70 mL) was added tert-butyldiphenylsilyl chloride (18.14 g, 66 mmol, 17.2 mL), and the solution was stirred at room temperature under a nitrogen atmosphere for 1 h. After removal of the solvent by evaporation, the residue was dissolved in CHCl3, washed with water and brine, dried (Na2SO4), filtered, and concentrated. After crystallization from hexane, the oily residue gave the title compound 4 as a white crystalline solid (20.6 g, 97%). M.P. 76° C.; 1H NMR (CDCl3) δ7.68-7.65 (m, 4H, arom.), 7.47-7.39 (m, 6H, arom.), 4.63-4.61 (m, 1H, H-5), 3.90-3.87 (dd, J=3 & 11 Hz, 1H, CH2OH), 3.70-3.67 (dd, J=3 & 11 Hz, 1H, CH2OH), 2.69-2.65 (m, 1H, H-3), 2.56-2.52 (m, 1H, H-3), 2.32-2.23 (m, 2H, H-4), 1.06 (s, 9H, t-Bu).
    • Example 4 (5S,3R)-5-[(tert-Butyldiphenylsilyl)hydroxymethyl]-dihydro-3-(phenylselenenyl)-2(3H)-furanone (5)
  • To a solution of 4 (5 g, 14.1 mmol) in anhydrous THF (50 mL) at −78° C. was added lithium bis(trimethylsilyl)amide (1 M solution in THF, 15.8 mL, 15.8 mmol) over a period of 10 min. After stirring at −78° C. for 1 h, Me3SiCl (1.918 g, 17.65 mmol) was added dropwise, and the reaction mixture was allowed to warm to room temperature. After being stirred at room temperature for 30 min, the mixture was cooled to −78° C., and a solution of PhSeBr (5,g, 21.19 mmol) in anhydrous THF 25 mL) was added rapidly. The mixture was diluted with ether (50 mL), washed with water until the color of organic layer changed from dark brown to light yellow, dried (Na2SO4), filtered, and evaporated. The resulting oily residue [containing 3R(α, 5) and 3S(β) isomers; TLC: hexane/EtOAc, 10:1; Rf=0.42 and 0.28, respectively] was purified by flash chromatography on silica gel eluting with hexane/EtOAc (99:1 to 95:5) to give the title compound 5 as a light yellow oil (4.22 g, 59%). 1H NMR (CDCl3) δ7.69-7.60 (m, 6H, arom.), 7.46-7.30 (m, 9H, arom.), 4.37-4,34 (m, 1H, H-5), 4.12-4.08 (m, 1H, H-3), 3.86-3.82 (dd, J=3 & 11 Hz, 1H, CH2OH), 3.62-3.59 (dd, J=3 & 11 Hz, 1H, CH2OH), 2.73-2.67 (m, 1H, H-4), 2.32-2.28 (m, 1H, H-4), 1.02 (s, 9H, t-Bu).
    • Example 5 1-O-Acetyl-5-O-(tert-butyldiphenylsilyl)-2,3-dideoxy-2-(phenylselenenyl)-α/β-D-erythro-pentofuranose (6)
  • To a stirred solution of 5 (13.68 g, 26.88 mmol) in anhydrous toluene (120 mL) at −78° C. was added diisobutylaluminum hydride (1 M solution in toluene, 43 mL, 43 mmol), and the solution was stirred at −78° C. for 2 h under an argon atmosphere. The reaction was quenched by addition of anhydrous MeOH (10 mL), and the mixture was allowed to warm to room temperature. After stirring at room temperature for 30 min, EtOAc (50 mL) and water (50 mL) were added. The resulting white precipitate was filtered, and the aqueous layer was extracted with EtOAc. The combined organic phase was washed with water and brine, dried (Na2SO4), filtered, and evaporated. The resulting oily residue was dissolved in anhydrous CH2Cl2 (60 mL), and cooled to 0° C. 4-Dimethylaminopyridine (DMAP, 5 mg) and pyridine (15 mL) were added, followed by Ac2O (8.22 g, 80.64 mmol). The mixture was stirred at 0° C. for 30 min, then at room temperature overnight. Evaporation of the solvent in vacuo afforded the title compound 6 as a clear yellow oil (13.45 g, 90%). This crude product was used directly without further purification. 1H NMR (CDCl3) δ 7.69-7.55 (m, 6H, arom.), 7.44-7.25 (m, 9H, arom.), 6.47-6.46 (d, H-1), 6.28 (s, H-1), 4.47-4,34 (m, 1H, H-4), 3.82-3.54 (m, 3H, H-5, H-2), 2.50-1.99 (m, 2H, H-3), 2.12, 1.86 (2s, 3H, CH3CO), 1.05, 1.96 (2s, 9H, t-Bu).
    • Example 6 β-D-5′-O-(tert-Butyldiphenylsilyl)-2′,3′-dideoxy-5-fluoro-2′-(phenylselenenyl)-cytidine (7)
  • A suspension of 5-fluorocytosine (1.61 g, 12.5 mmol) and (NH4)2SO4 (165 mg, 1.25 mmol) in hexamethyldisilazane (20 mL) was heated at reflux for 2 h under an argon atmosphere, and then evaporated to dryness in vacuo. To the residue was added a solution of 6 (5.53 g, 10.0 mmol) in anhydrous 1,2-dichloroethane (25 mL), and the mixture was cooled to 5° C. TMSOTf (2.0 mL, 11 mmol) was added, and the resulting solution was stirred at 5° C. for 15 min under an argon atmosphere, then at room temperature for another 30 min. The solution was poured into a mixture of EtOAc and saturated aqueous NaHCO3 with stirring. The organic layer was separated, washed with saturated NaHCO3 solution, water, and brine, dried (Na2SO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (99:1 to 96:4) to give 7 (5.36 g, 86%) as a white solid. M.P. 163-164° C.; 1H NMR (CDCl3) δ7.95 (d, J=6.4 Hz, 1H, H-6), 7.67-7.62 (m, 6H, arom.), 7.47-7.25 (m, 9H, arom.), 6.90 (bs, 1H, NH), 6.15-6.14 (m, 1H, H-1′), 5.40 (bs, 1H, NH), 4.32-4.30 (m, 1H, H-4′), 4.12-4.08 (m, 1H, H-5′a), 3.84-3.83 (m, 1H, H-2′), 3.65 (dd, J=2.4 & 11.2 Hz, 1H, H-5′b), 2.45-2.42, 2.01-1.98 (2m, 2H, H-3′), 1.08 (s, 9H, t-Bu); 13C NMR (CDCl3) δ157.0, 156.8, 153.3, 137.3, 135.6, 135.5, 135.4, 134.9, 132.6, 132.3, 130.1, 130.0, 129.2, 128.3, 127.9, 127.4, 125.5, 125.2, 91.0, 80.2, 64.8, 45.4, 32.3, 26.9, 19.2.
    • Example 7 β-D-5′-O-(tert-Butyldiphenylsilyl)-2′,3′-dideoxy-5-fluorocytidine (8)
  • A suspension of 7 (4.976 g, 8 mmol), Et3B (1 M solution in hexane, 8.8 mL, 8.8 mmol), and n-Bu3SnH (3.23 mL, 12 mmol) in anhydrous benzene (40 mL) was stirred at room temperature under an argon atmosphere for 5 h. After evaporation of the solvent, the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (99:1 to 96:4) to give the title compound 8 as a pale yellow foam (3.45 g, 92%). 1H NMR (CDCl3) δ8.14 (d, J=6.4 Hz, 1H, H-6), 7.71-7.66 (m 4H, arom.), 7.49-7.38 (m, 6H, arom.), 6.04 (m, 1H, H-1′), 4.17-4.12 (m, 1H, H-4′), 4.12-4.08 (m, 1H, H-5′a), 3.73-3.69 (m, 1H, H-5′b), 2.54-2.44, 2.18-2.09 (2m, 2H, H-2′), 2.05-1.95, 1.89-1.82 (2m, 2H, H-3′), 1.10 (s, 9H, t-Bu).
    • Example 8 β-D-5′-O-(tert-Butyldiphenylsilyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (9)
  • To a solution,of 7 (15.47 g, 24.87 mmol) in CH2Cl2 (150 mL) containing 5 drops of pyridine at 0° C. was added a solution of H2O2 (15.5 mL of 30% solution) dropwise over a period of 15 min. After stirring at 0° C. for 20 min, and at room temperature for 30 min, the reaction solution was diluted with CHCl3 (200 mL), washed with H2O, saturated NaHCO3 solution, and H2O, dried (Na2SO4), filtered, and concentrated. The residue, after purification by chromatography over silica gel eluted with CH2Cl2/MeOH (96:4), gave 9 as a pale yellow foam (9.907 g, 86%). M.P. 150-152° C.; 1H NMR (CDCl3) δ7.88 (d, J=6.4 Hz, 1H, H-6), 7.66-7.65 (m, 4H, arom.), 7.47-7.37 (m, 6H, arom.), 7.00-6.99 (m, 1H, H-1′), 6.50 (bs, 1H, NH), 6.12 (d, J=6.0 Hz, 1H, H-3′), 5.98 (d, J=4.8 Hz, 1H, H-2′), 5.35 (bs, 1H, NH), 4.89 (bs, 1H, H-4′), 4.00 (dd, J=3.2 & 11.6 Hz, 1H, H-5′a), 3.81 (dd, J=3.6 & 12.4 Hz, 1H, H-5′b), 1.06 (s, 9H, t-Bu). 13C NMR (CDCl3) δ157.3, 157.1, 153.6, 137.5, 135.6, 135,4, 135.1, 133.3, 132.8, 132.6, 130.1, 130.0, 127.9, 127.8, 127.4, 126.1, 125.8, 91.3, 87.3, 65.1, 26.9, 19.2.
    • Example 9 β-D-2′,3′-Dideoxy-5-fluoro-N4-(4-iodobenzoyl)cytidine (10)
  • To a solution of 8 (131 mg, 0.28 mmol) and DMAP (5 mg) in anhydrous CH2Cl2 (2 mL) and Et3N (0.5 mL) at 0° C. was added 4-iodobenzoyl chloride (85 mg, 0.31 mmol). The reaction mixture was stirred at 0° C. for 30 min, then at room temperature for another 3 h. After removal of the solvent by evaporation, the residue was mixed with THF (3 mL), and TBAF (1 M solution in THF, 0.28 mL, 0.28 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound 10 as a yellow powder (48 mg, 37%). 1H NMR (DMSO-d6) δ8.9 (bs, 1H, NH), 7.90-7.73 (m, 5H, H-6, arom.), 5.91 (bs, 1H, H-1′), 5.10 (m, 1H, OH), 4.14 (m, 1H, H-4′), 3.80, 3.57 (2m, 2H, H-5′), 2.35, 2.08 (2m, 2H, H-2′), 1.86 (m, 2H, H-3′).
  • By following the same procedures as above but using the corresponding carboxylic acid chloride starting materials, the following compounds are also prepared:
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(4-fluorobenzoyl)cytidine (11)
  • 1H NMR (DMSO-d6) δ8.9 (bs, 1H, NH), 8.05, 7.34 (2m, 5H, H-6, arom.), 5.90 (d, 1H, H-1′), 5.25 (m, 1H, OH), 4.11 (m, 1H, H-4′), 3.79, 3.58 (2m, 2H, H-5′), 2.35, 2.08 (2m, 2H, H-2′), 1.85 (m, 2H, H-3′).
    • β-D-N4-(4-chlororobenzoyl)-2′,3′-dideoxy-5-fluorocytidine (12)
  • 1H NMR (DMSO-d6) δ8.9 (bs, 1H, NH), 7.99, 7.60 (2m, 5H, H-6, arom.), 5.90 (bs, 1H, H-1′), 5.38 (m, 1H, OH), 4.14 (m, 1H, H-4′), 3.82, 3.58 (2m, 2H, H-5′), 2.35, 2.08 (2m, 2H, H-2′), 1.84 (m, 2H, H-3′).
    • β-D-N4-(4-bromobenzoyl)-2′,3′-dideoxy-5-fluorocytidine (13)
  • 1H NMR (DMSO-d6) δ8.9 (bs, 1H, NH), 7.93, 7.72 (2m, 5H, H-6, arom.), 5.91 (d, 1H, H-1′), 5.25 (m, 1H, OH), 4.11 (m, 1H, H-4′), 3.79, 3.58 (2m, 2H, H-5′), 2.35, 2.07 (2m, 2H, H-2′), 1.85 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(3-fluorobenzoyl)cytidine (14)
  • 1H NMR (CDCl3) δ8.37 (d, 1H, H-6), 8.09-7.24 (m, 4H, arom.), 6.08 (m, 1H, H-1′), 4.27 (m, 1H, H-4′), 4.13, 3.82 (2d, 2H, H-5′), 2.48, 2.20 (2m, 2H, H-2′), 2.02 (m, 2H, H-3′).
    • β-D-N4-(3-Chlorobenzoyl)-2′,3′-dideoxy-5-fluorocytidine (15)
  • 1H NMR (DMSO-d6) δ8.8 (bs, 1H, NH), 8.01-7.53 (m, 5H, H-6, arom.), 5.91 (d, 1H, H-1′), 5.34 (t, 1H, OH), 4.12 (m, 1H, H-4′), 3.81, 3.58 (2d, 2H, H-5′), 2.40, 2.10 (2m, 2H, H-2′), 1.85 (m, 2H, H-3′).
    • β-D-N4-(3-Bromobenzoyl)-2′,3′-dideoxy-5-fluorocytidine (16)
  • 1H NMR (DMSO-d6) δ8.75 (bs, 1H, NH), 8.14-7.45 (m, 5H, H-6, arom.), 5.90 (d, 1H, H-1′), 5.29 (bs, 1H, OH), 4.11 (m, 1H, H-4′), 3.80, 3.58 (2m, 2H, H-5′), 2.40, 2.08 (2m, 2H, H-2′), 1.85 (m, 2H, H-3′).
    • β-D-N4-p-Anisoyl-2′,3′-dideoxy-5-fluorocytidine (17)
  • 1H NMR (DMSO-d6) δ8.1 (bs, 1H, NH), 7.97, 7.04 (2m, 5H, H-6, arom.), 5.95 (m, 1H, H-1′), 4.50 (m, 1H, OH), 4.40 (m, 1H, H-4′), 3.82 (s, 3H, CH3), 3.80 (m, 2H, H-5′), 2.35, 2.05 (2m, 2H, H-2′), 1.90 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(4-nitrobenzoyl)cytidine (18)
  • 1H NMR (DMSO-d6) δ8.9 (bs, 1H, NH), 8.32, 8.23 (2m, 5H, H-6, arom.), 5.92 (d, 1H, H-1′), 5.30 (bs, 1H, OH), 4.11 (m, 1H, H-4′), 3.79, 3.59 (2m, 2H, H-5′), 2.35, 2.10 (2m, 2H, H-2′), 1.86 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(3-nitrobenzoyl)cytidine (19)
  • 1H NMR (DMSO-d6) δ8.76 (d, 1H, H-6), 8.7 (bs, 1H, NH), 8.40, 7.80 (2m, 4H, arom.), 5.95 (d, 1H, H-1′), 5.30 (m, 1H, OH), 4.08 (m, 1H, H-4′), 3.79, 3.58 (2m, 2H, H-5′), 2.35, 2.08 (2m, 2H, H-2′), 1.85 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(2-nitrobenzoyl)cytidine (20)
  • 1H NMR (CDCl3) δ8.49 (d, 1H, H-6), 7.96-7.50 (m, 4H, arom.), 6.02 (d, 1H, H-1′), 4.22 (m, 1H, H-4′), 4.11, 3.81 (2d, 2H, H-5′), 2.45, 2.15 (2m, 2H, H-2′), 1.98 (m, 2H, H-3′).
    • β-D-N4-Benzoyl-2′,3′-dideoxy-5-fluorocytidine (21)
  • 1H NMR (DMSO-d6) δ8.2 (bs, 1H, NH), 7.98, 7.52 (2m, 5H, H-6, arom.), 5.95 (d, 1H, H-1′), 5.74 (bs, 1H, OH), 4.57, 4.40 (2m, 3H, H-4′, H-5′), 2.35, 2.08 (2m, 2H, H-2′), 1.90 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-p-toluoylcytidine (22)
  • 1H NMR (CDCl3) δ8.31 (d, 1H, H-6), 8.15, 7.24 (2m, 4H, arom.), 6.08 (m, 1H, H-1′), 4.25 (m, 1H, H-4′), 4.10, 3.82 (2m, 2H, H-5′), 2.42 (s, 3H, CH3), 2.47, 2.15 (2m, 2H, H-2′), 2.00 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-m-toluoylcytidine (23)
  • 1H NMR (CDCl3) δ8.31 (d, 1H, H-6), 8.07, 7.36 (2m, 4H, arom.), 6.09 (m, 1H, H-1′), 4.25 (m, 1H, H-4′), 4.11, 3.83 (2m, 2H, H-5′), 2.45, 2.18 (2m, 2H, H-2′), 2.42 (s, 3H, CH3), 2.00 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-o-toluoylcytidine (24)
  • 1H NMR (DMSO-d6) δ8.8 (bs, 1H, NH), 7.55-7.26 (m, 6H, H-6, arom.), 5.88 (d, 1H, H-1′), 5.30 (t, 1H, OH), 4.12 (m, 1H, H-4′), 3.82, 3.58 (2m, 2H, H-5′), 2.41 (s, 3H, CH3), 2.32, 2.07 (2m, 2H, H-2′), 1.83 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-N4-(4-ethylbenzoyI)-5-fluorocytidine (25)
  • 1H NMR (CDCl3) δ8.24 (d, 1H, H-6), 8.18, 7.29 (2m, 4H, l arom.), 6.10 (d, 1H, H-1′), 4.24 (m, 1H, H-4′), 4.10, 3.80 (2m, 2H, H-5′), 2.72 (q, 2H, CH2), 2.50, 2.20 (2m, 2H, H-2′), 2.00 (m, 2H, H-3′), 1.26 (t, 3H, CH3).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(4-n-propylbenzoyl)cytidine (26)
  • 1H NMR (CDCl3) δ8.30 (d, 1H, H-6), 8.17, 7.25 (2m, 4H, arom.), 6.09 (m, 1H, H-1′), 4.24 (m, 1H, H-4′), 4.11, 3.80 (2m, 2H, H-5′), 2.65 (t, 2H, CH2), 2.45, 2.18 (2m, 2H, H-2′), 2.02 (m, 2H, H-3′), 1.66 (m, 2H, CH2), 0.94 (t, 3H, CH3).
    • β-D-N4-(4-n-Butylbenzoyl)-2′,3′-dideoxy-5-fluorocytidine (27)
  • 1H NMR (CDCl3) δ8.34 (d, 1H, H-6), 8.17, 7.25 (2m, 4H, arom.), 6.10 (m, 1H, H-1′), 4.25 (m, 1H, H-4′), 4.13, 3.82 (2m, 2H, H-5′), 2.68 (t, 2H, CH2), 2.50, 2.20 (2m, 2H, H-2′), 2.02 (m, 2H, H-3′), 1.66 (m, 2H, CH2), 1.37 (m, 2H, CH2), 0.93 (t, 3H, CH3).
    • β-D-N4-(4-tert-Butylbenzoyl)-2′,3′-dideoxy-5-fluorocytidine (28)
  • 1H NMR (CDCl3) δ8.31 (d, 1H, H-6), 8.17, 7.48 (2m, 4H, arom.), 6.08 (m, 1H, H-1′), 4.25 (m, 1H, H-4′), 4.10, 3.80 (2m, 2H, H-5′), 2.47, 2.15 (2m, 2H, H-2′), 2.00 (m, 2H, H-3′), 1.35 (s, 9H, t-Bu).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(2-furoyl)cytidine (29)
  • 1H NMR (CDCl3) δ8.37 (d, 1H, H-6), 7.62, 7.38, 6.52 (3m, 3H, furoyl), 6.07 (m, 1H, H-1′), 4.25 (m, 1H, H-4′), 4.11, 3.80 (2m, 2H, H-5′), 2.47, 2.17 (2m, 2H, H-2′), 2.01 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(2-thiophenecarbonyl)cytidine (30)
  • 1H NMR (CDCl3) δ8.32 (d, 1H, H-6), 7.96 (d, 1H, thiophenyl), 7.60 (d, 1H, thiophenyl), 7.13 (t, 1H, thiophenyl), 6.08 (m, 1H, H-1′), 4.25 (m, 1H, H-4′), 4.13, 3.82 (2m, 2H, H-5′), 2.47, 2.17 (2m, 2H, H-2′), 2.02 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(nicotinoyl)cytidine (31)
  • 1H NMR (CDCl3) δ9.11 (s, 1H, nicotinoyl), 8.53 (d, 1H, H-6), 8.75, 8.54, 7.40 (3m, 3H, nicotinoyl), 6.10 (m, 1H, H-1′), 4.27 (m, 1H, H-4′), 4.16, 3.83 (2m, 2H, H-5′), 2.48, 2.20 (2m, 2H, H-2′), 2.03 (m, 2H, H-3′).
    • β-D-2′,3′-Dideoxy-5-fluoro-N4-(benzo[b]thiophene-2-carbonyl)cytidine (32)
  • 1H NMR (DMSO-d6) δ8.7 (bs, 1H, NH), 8.00, 7.45 (2m, 6H, H-6, arom.), 5.91 (d, 1H, H-1′), 5.32 (m, 1H, OH), 4.11 (m, 1H, H-4′), 3.80, 3.58 (2m, 2H, H-5′), 2.44, 2.08 (2m, 2H, H-2′), 1.86 (m, 2H, H-3′).
    • β-D-N4-2′,3′-dideoxy-5-fluorocytidine (33)
  • 1H NMR (CDCl3) δ8.45 (d, 1H, H-6), 6.04 (d, 1H, H-1′), 4.25 (m, 1H, H-4′), 4.12, 3.81 (2m, 2H, H-5′), 2.50-1.20 (m, 15H, H-2′, H-3′, c-hexyl).
    • Example 10 β-D-N4-Butyryl-2′,3′-dideoxy-5-fluorocytidine (34)
  • To a solution of 8 (131 mg, 0.28 mmol) and DMAP (5 mg) in anhydrous CH2Cl2 (2 mL) and Et3N (0.5 mL) at 0° C. was added butyric anhydride (52 mg, 0.33 mmol). The reaction mixture was stirred at 0° C. for 30 min, then at room temperature for another 2 h. After removal of the solvent by evaporation, the residue was mixed with THF (3 mL), and TBAF (1 M solution in THF, 0.30 mL, 0.30 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound 34 as a white solid (31 mg, 35%). 1H NMR (DMSO-d6) δ 8.21 (d, 1H, H-6), 5.92 (t, 1H, H-1′), 4.26 (m, 1H, H-4′), 4.22 (m, 2H, H-5′), 2.30 (t, 2H, CH2), 2.38, 2.04 (2m, 2H, H-2′), 1.90 (m, 2H, H-3′), 1.58 (m, 2H, CH2), 0.85 (t, 3H, CH3).
    • Example 11 β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-(4-fluorobenzoyl)cytidine (35)
  • To a solution of 9 (140 mg, 0.3 mmol) and DMAP (5 mg) in anhydrous CH2Cl2 (2 mL) and Et3N (0.5 mL) at 0° C. was added 4-fluorobenzoyl chloride (52 mg, 0.33 mmol). The reaction mixture was stirred at 0° C. for 30 min, then at room temperature for another 2 h. After removal of the solvent by evaporation, the residue was mixed with THF (3 mL), and TBAF (1 M solution in THF, 0.30 mL, 0.30 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound 35 as a pale yellow solid (33 mg, 32%). 1H NMR (DMSO-d6) δ8.07, 7.35 (2m, 5H, H-6, arom.), 6.84 (bs, 1H, H-1′), 6.42 (m, 1H, H-2′), 5.98 (m, 1H, H-3′), 5.22 (m, 1H, OH), 4.88 (m, 1H, H-4′), 3.66 (m, 2H, H-5′).
  • By following the same procedures as above but using the corresponding carboxylic acid chloride starting materials, the following compounds are also prepared:
    • β-D-N4-(4-Chlorobenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (36)
  • 1H NMR (DMSO-d6) δ8.00, 7.59 (2m, 5H, H-6, arom.), 6.84 (bs, 1H, H-1′), 6.42 (m, 1H, H-2′), 5.97 (m, 1H, H-3′), 5.22 (m, 1H, OH), 4.88 (m, 1H, H-4′), 3.66 (m, 2H, H-5′).
    • β-D-N4-(4-Bromobenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (37)
  • 1H NMR (DMSO-d6) δ7.86, 7.72 (2m, 5H, H-6, arom.), 6.85 (bs, 1H, H-1′), 6.42 (m, 1H, H-2′), 5.97 (m, 1H, H-3′), 4.88 (m, 1H, H-4′), 3.90-3.65 (m, 2H, H-5′).)
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-(4-iodobenzoyl)cytidine (38)
  • 1H NMR (DMSO-d6) δ7.90-7.60 (2m, 5H, H-6, arom.), 6.83 (bs, 1H, H-1′), 6.42 (m, 1H, H-2′), 5.97 (m, 1H, H-3′), 5.22 (m, 1H, OH), 4.88 (m, 1H, H-4′), 3.66 (m, 2H, H-5′).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-(3-fluorobenzoyl)cytidine (39)
  • 1H NMR (DMSO-d6) δ7.85-7.39 (m, 5H, H-6, arom.), 6.84 (bs, 1B, H-1′), 6.42 (m, 1H, H-2′), 5.98 (m, 1H, H-3′), 5.22 (m, 1H, OH), 4.88 (m, 1H, H-4′), 3.66 (m, 2H, H-5′). β- D-N4-(3-Chlorobenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (40)
  • 1H NMR (DMSO-d6) δ8.00-7.40 (2m, 5H, H-6, arom.), 6.84 (bs, 1H, H-1′), 6.42 (m, 1H, H-2′), 5.97 (m, 1H, H-3′), 5.22 (m, 1H, OH), 4.88 (m, 1H, H-4′), 3.66 (m, 2H, H-5′).
    • β-D-N4-(3-Bromobenzoyl)-2′,3′-didehydro-2′,3′-dideoxy)-5-fluorocytidine (41)
  • 1H NMR (DMSO-d6) δ8.16-7.34 (m, 5H, H-6, arom.), 6.84 (bs, 1H, H-1′), 6.46 (m, 1H, H-2′), 5.98 (m, 1H, H-3′), 5.23 (t, 1H, OH), 4.88 (bs, 1H, H-4′), 3.68 (m, 2H, H-5′).
    • β-D-N4-p-Anisoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (42)
  • 1H NMR (CDCl3+DMSO-d6) δ7.72 (d, 2H, arom.), 7.12 (d, J=7.2 Hz, 1H, H-6), 6.93 (m, 1H, H-1′), 6.48 (d, 2H, arom.), 6.45 (m, 1H, H-2′), 5.87 (m, 1H, H-3′), 5.78 (m, 1H, H-4′), 4.03 (s, 3H, OCH3), 3.40 (m, 2H, H-5′).
    • β-D-N4-m-Anisoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (43)
  • 1H NMR (CDCl3) δ7.35-6.60 (m, 5H, H-6, H-1′, arom.), 6.60 (m, 1H, arom.), 6.58 (m, 1H, H-2′), 5.82 (m, 1H, H-3′), 5.74 (m, 1H, H-4′), 3.99 (s, 3H, OCH3), 3.36 (m, 2H, H-5′).
    • β-D-N4-o-Anisoyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (44)
  • 1H NMR (DMSO-d6) δ10.75(bs, 1H, NH), 8.55 (d, 1H, H-6), 7.77-7.08 (m, 4H, arom.), 6.84 (bs, 1H, H-1′), 6.40 (m, 1H, H-2′), 5.99 (m, 1H, H-3′), 5.19 (t, 1H, OH), 4.89 (m, 1H, H-4′), 3.91 (s, 3H, OCH3), 3.66 (m, 2H, H-5′).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-(4-nitrobenzoyl)cytidine (45)
  • 1H NMR (DMSO-d6) δ8.34-8.20 (m, 5H, H-6, arom.), 6.83 (bs, 1H, H-1′), 6.42 (m, 1H, H-2′), 5.95 (m, 1H, H-3′), 5.18 (m, 1H, OH), 4.87 (bs, 1H, H-4′), 3.66 (m, 2H, H-5′).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-(3-nitrobenzoyl)cytidine (46)
  • 1H NMR (DMSO-d6) δ8.74-7.38 (m, 5H, H-6, arom.), 6.83 (bs, 1H, H-1′), 6.42 (m, 1H, H-2′), 5.97 (m, 1H, H-3′), 5.18 (m, 1H, OH), 4.87 (bs, 1H, H-4′), 3.66 (m, 2H, H-5′).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-(2-nitrobenzoyl)cytidine (47)
  • 1H NMR (DMSO-d6) δ8.14-7.71 (m, 5H, H-6, arom.), 6.83 (bs, 1H, H-1’), 6.42 (m, 1H, H-2′), 5.95 (m, 1H, H-3′), 5.18 (m, 1H, OH), 4.87 (bs, 1H, H-4′), 3.66 (m, 2H, H-5′).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-p-toluoylcytidine (48)
  • 1H NMR (DMSO-d6) δ7.87-7.31 (2m, 5H, H-6, arom.), 6.83 (m, 1H, H-1′), 6.40 (m, 1H, H-2′), 5.95 (m, 1H, H-3′), 5.18 (m, 1H, OH), 4.85 (m, 1H, H-4′), 3.66 (m, 2H, H-5′), 2.37 (s, 3H, CH3).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-m-toluoylcytidine (49)
  • 1H NMR (DMSO-d6) δ7.78, 7.42 (2m, 5H, H-6, arom.), 6.83 (bs, 1H, H-1′), 6.41 (m, 1H, H-2′), 5.97 (m, 1H, H-3′), 5.17 (bs, 1H, OH), 4.87 (m, 1H, H-4′), 3.66 (m, 2H, H-5′), 2.36 (s, 3H, CH3).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-o-toluoylcytidine (50)
  • 1H NMR (DMSO-d6) δ7.60-7.40 (m, 5H, H-6, arom.), 6.83 (bs, 1H, H-1′), 6.40 (m, 1H, H-2′), 5.99 (m, 1H, H-3′), 5.17 (bs, 1H, OH), 4.88 (m, 1H, H-4′), 3.66 (m, 2H, H-5′), 2.42 (s, 3H, CH3).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-N4-(4-ethyllbenzoyl)-5-fluorocytidine (51)
  • 1H NMR (CDCl3) δ8.19 (m, 2H, arom.), 8.09 (d, 1H, H-6), 7.28 (m, 2H, arom.), 7.03 (m, 1H, H-1′), 6.39 (m, 1H, H-2′), 5.91 (m, 1H, H-3′), 5.20 (m, 1H, OH), 4.97 (m, 1H, H-4′), 4.02-3.85 (m, 2H, H-5′), 2.71 (q, 2H, CH2), 1.26 (t, 3H, CH3).
    • β-D-N4-(4-n-Butylbenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluoro-4cytidine (52)
  • 1H NMR (CDCl3) δ8.19 (m, 2H, arom.), 8.12 (d, 1H, H-6), 7.26 (m, 2H, arom.), 7.04 (m, 1H, H-1′), 6.37 (m, 1H, H-2′), 5.92 (m, 1H, H-3′), 4.99 (m, 1H, H-4′), 4.03-3.87 (m, 2H, H-5′), 2.68 (t, 2H, CH2), 1.66 (m, 2H, CH2), 1.36 (m, 2H, CH2), 0.93 (t, 3H, CH3).
    • β-D-N4-(4-tert-Butylbenzoyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (53)
  • 1H NMR (CDCl3) 88.19 (m, 2H, arom.), 8.09 (d, 1H, H-6), 7.48 (m, 2H, arom.), 7.04 (m, 1H, H-1′), 6.36 (m, 1H, H-2′), 5.91 (m, 1H, H-3′), 5.22 (m, 1H, OH), 4.98 (m, 1H, H-4′), 4.02-3.86 (m, 2H, H-5′), 1.34 (s, 9H, t-Bu).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-(2-thiophenecarbonyl)cytidine (54)
  • 1H NMR (DMSO-d6) δ8.30-7.20 (m, 4H, H-6, thiophene), 6.82 (m, 1H, H-1′), 6.42 (m, 1H, H-2′), 5.93 (m, 1H, H-3′), 5.16 (m, 1H, OH), 4.85 (m, 1H, H-4′), 3.65 (m, 2H, H-5′).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-nicotinoylcytidine (55)
  • 1H NMR (DMSO-d6) δ9.11-7.53 (m, 5H, H-6, nicotinoyl), 6.83 (bs, 1H, H-1′), 6.42 (d, 1H, H-2′), 5.95 (m, 1H, H-3′), 5.18 (m, 1H, OH), 4.88 (m, 1H, H-4′), 3.66 (m, 2H, H-5′).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-(benzo[b]thiophene-2-carbonyl)cytidine (56)
  • 1H NMR (DMSO-d6) δ8.34-7.44 (m, 6H, arom.), 6.83 (bs, 1H, H-1’), 6.41 (d, 1H, H-2′), 5.94 (m, 1H, H-3′), 5.18 (m, 1H, OH), 4.85 (m, 1H, H-4′), 3.66 (m, 2H, H-5′).
    • β-D-N4-(Cyclopentanecarbonyl)-2′,3′-didehydro-2′,3′-dideoxy-5 -fluorocytidine (57)
  • 1H NMR (DMSO-d6) δ10.60 (bs, 1H, NH), 8.48 (d, 1H, H-6), 6.81 (bs, 1H, H-1′), 6.38 (m, 1H, H-2′), 5.97 (m, 1H, H-3′), 5.16 (t, 1H, OH), 4.88 (bs, 1H, H-4′), 3.65 (m, 2H, H-5′), 3.06 (m, 1H, CH), 1.85-1.51 (m, 8H, 4 CH2).
    • β-D-N4-(Cyclohexanecarbonyl)-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (58)
  • 1H NMR (DMSO-d6) δ10.50 (bs, 1H, NH), 8.47 (d, 1H, H-6), 6.81 (d, 1H, H-1′), 6.38 (m, 1H, H-2′), 5.97 (m, 1H, H-3′), 5.16 (t, 1H, OH), 4.88 (bs, 1H, H-4′), 3.65 (m, 2H, H-5′), 2.60 (m, 1H, CH), 1.81-1.17 (m, 10H, 5 CH2).
    • β-D-2′,3′-Didehydro-2′,3′-dideoxy-5-fluoro-N4-heptanoylcytidine (59)
  • 1H NMR (CDCl3) δ8.27 (d, 1H, H-6), 7.00 (bs, 1H, H-1′), 6.28 (m, 1H, H-2′), 5.99 (m, 1H, H-3′), 5.30 (bs, 1H, OH), 5.01 (bs, 1H, H-4′), 4.03-3.86 (m, 2H, H-5′), 1.68, 1.30 (2m, 10H, 5 CH2), 0.88 (t, 3H, CH3).
    • Example 12 β-D-N4-Butyryl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (60)
  • To a solution of 9 (140 mg, 0.3 mmol) and DMAP (5 mg) in anhydrous CH2Cl2 (2 mL) and Et3N (0.5 mL) at 0° C. was added butyric anhydride (52 mg, 0.33 mmol). The reaction mixture was stirred at 0° C. for 30 min, then at room temperature for another 2 h. After removal of the solvent by evaporation, the residue was mixed with THF (3 mL), and TBAF (1 M solution in THF, 0.30 mL, 0.30 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound 60 as a white solid (31 mg, 35%). 1H NMR (DMSO-d6) δ8.47 (d, 1H, H-6), 6.82 (t, 1H, H-1′), 6.39 (m, 1H, H-2′), 5.98 (m, 1H, H-3′), 5.20 (t, 1H, OH), 4.89 (m, 1H, H-4′), 3.66 (m, 2H, H-5′), 2.51 (t, 2H, CH2), 1.58 (m, 2H, CH2), 0.89 (t, 3H, CH3).
    • Example 13 Anti-HIV (in PBM Cells) Assay
  • Anti-HIV-1 activity of the compounds was determined in human peripheral blood mononuclear (PBM) cells as described previously (Schinazi R. F., McMillan A., Cannon D., Mathis R., Lloyd R. M. Jr., Peck A., Sommadossi J.-P., St. Clair M., Wilson J., Furman P. A., Painter G., Choi W.-B., Liotta D. C. Antimicrob. Agents Chemother. 1992, 36, 2423; Schinazi R. F., Sommadossi J.-P., Saalmann V., Cannon D., Xie M.-Y., Hart G., Smith G., Hahn E. Antimicrob. Agents Chemother. 1990, 34, 1061). Stock solutions (20-40 mM) of the compounds were prepared in sterile DMSO and then diluted to the desired concentration in growth medium. Cells were infected with the prototype HIV-1LAI at a multiplicity of infection of 0.01. Virus obtained from the cell supernatant was quantified on day 6 after infection by a reverse transcriptase assay using (rA)n·(dT)12-18 as template-primer. The DMSO present in the diluted solution (<0.1%) had no effect on the virus yield. AZT was included as positive control. The antiviral EC50 and EC90 were obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M. S. & Schinazi R. F. Antiviral Res. 1994, 25, 1-11).
    • Anti-HIV (in MT-2 Cells) Assay
  • In a second antiviral testing system, the potency of the compounds was determined by measurement of viral RNA accumulation in HIV-1RF infected MT-2 cells (Bacheler L T, Paul M, Otto M J, Jadhav P K, Stone B A & Miller J A (1994) An assay for HIV RNIn infected cell lysates, and its use for rapid evaluation of antiviral efficacy. Antivir. Chem. Chemother. 5:111-121). The virus titer was established to determine the dilution producing 15 to 30 ng/RNA per well of HIV RNIn 3 days of infection. HIV-1 RNA was quantified using biotinylated capture and alkaline phosphatase-derivatized reporter oligonucleotides as described previously (Charvet A-S, Camplo M, Faury P, Graciet J C, Mourier N, Chermann J C & Kraus J L (1994) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2′,3′-dideoxy-3′-thiacytidine conjugates. J. Med. Chem. 37:2216-2223). In a third system, the effect of analogs on the replication of HIV-1NL4-3 was determined via the InterCompany Consortium consensus p24 assay as previously described (Jadhav P K & MacKay M F (1997) Cyclic urea amide: HIV-1 protease inhibitors with low nanomolar potency against both wild types and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40:181-190). Recombinant viruses were recovered by transfecting the appropriate NL4-3 plasmid by lipofection. Virus stocks recovered 7 to 10 days post-transfection were titered on MT-4 cells to determine if the dilution produced 1,000 to 3,000 ng p24 in 4 days. This dilution was then used in drug susceptibility assays, where drug was added 24 h post infection of cells, and p24 quantified by ELISA 3 days later.
    • Example 14 Anti-HBV Assay
  • The anti-HBV activity of the compounds was determined by treating the AD-38 cell line carrying wild type HBV under the control of tetracycline (Ladner S. K., Otto M. J., Barker C. S., Zaifert K., Wang G. H., Guo J. T., Seeger C. & King R. W. Antimicrob. Agents Chemother. 1997, 41, 1715-1720). Removal of tetracycline from the medium [Tet (−)] results in the production of HBV. The levels of HBV in the culture supernatant fluids from cells treated with the compounds were compared with that of the untreated controls. Control cultures with tetracycline [Tet (+)] were also maintained to determine the basal levels of HBV expression. 3TC was included as positive control (see Tables 1, 2).
    • Example 15 Cytotoxicity Assay
  • The toxicity of, the compounds was assessed in Vero, human PBM, CEM (human lymphoblastoid), MT-2, and HepG2 cells, as described previously (Schinazi R. F., Sommadossi J.-P., Saalmann V., Cannon D. L., Xie M.-Y., Hart G. C., Smith G. A. & Hahn E. F. Antimicrob Agents Chemother. 1990, 34, 1061-1067). Cycloheximide was included as positive cytotoxic control, and untreated cells exposed to solvent were included as negative controls. The cytotoxicity IC50 was obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M. S. & Schinazi R. F. Antiviral Res. 1994, 25, 1-11) (see Tables 1, 2).
  • TABLE 1
    Anti-HIV activity and cytotoxicity of N4-acyl-2′,3′-dideoxy-5-fluorocytidine
    Anti-HIV-1
    activity in different Cytotoxicity in different cells
    cells (EC90, μM) (IC50, μM)
    Cmpd. No. N4-substituent PBM MT-2 MT-4 PBM CEM Vero MT-2 HepG2
    D-D2FC H 0.32 1.4 1.3 >100 >100 >100 >50 >100
    10 p-IBz 0.019 0.025 0.17 >100 >100 >100 >50 >100
    11 p-FBz 0.027 0.32 0.61 >100 45.7 >100 >50 >100
    12 p-ClBz 0.02 0.22 0.37 >100 33.4 >100 >50 7.3
    13 p-BrBz 0.03 0.14 0.30 >100 31.6 >100 >50 >100
    14 m-FBz 0.106 0.46 0.43 >100 80.8 >100 >50 >100
    15 m-ClBz 0.08 0.4 0.51 >100 68.1 91.6 >50 >100
    16 m-BrBz 0.145 0.51 0.42 >100 40.6 80.6 >50 >100
    17 p-MeOBz 8.31 6 69.2 31.6 5.3 16 4.5
    18 p-NO2Bz 0.18 0.4 0.30 >100 >100 >100 >50 >100
    19 m-NO2Bz 1.6 1.8 1.59 >100 >100 >100 >50 >100
    20 o-NO2Bz 1.5 0.7 >100 >100 >100 >50 >100
    21 Bz 1.29 1.2 67.0 38.5 5.8 19 15.3
    22 p-MeBz 0.028 0.31 0.23 >100 >100 >100 >50 >100
    23 m-MeBz 0.012 0.24 8.4 >100 61.1 >50 >100
    24 o-MeBz 1.2 6.8 20.6 22.5 39.6 >50 >100
    25 p-EtBz 0.03 0.12 0.22 >100 89.8 >100 50 >100
    26 p-PrBz 0.017 0.1 0.22 >100 >100 >100 >50 >100
    27 p-BuBz 0.31 ND 1.1 1.3 3.2 ND 1.9
    28 p-t-BuBz 0.088 0.6 ND 12.5 6.0 25.9 50 21.3
    29 o-furoyl 1.5 0.9 ND 16.9 5.7 29.6 >50 31.1
    30 o- 0.052 0.4 ND 19.4 13.7 23.9 >50 37.9
    thiophenecarbonyl
    31 Nicotinoyl 0.17 5.9 ND 8.8 5.5 28.1 >50 19.4
    32 benzo[b]thiophene- 0.19 0.3 ND 23.5 4.5 39.6 >50 1.3
    2-carbonyl
    33 c-hexanecarbonyl 0.086 0.3 ND 4.5 6.4 11.8 50 6.5
    34 Butyryl 1.6 0.71 ND 17.1 31.6 5.8 7.2 7.6
    ND = not determined
  • TABLE 2
    Anti-HIV activity and cytotoxicity of N4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
    Anti-HIV-1
    activity in different Cytotoxicity in different cells
    Compd. cells (EC90, μM) (IC50, μM)
    No. N4-substituent PBM MT-2 MT-4 PBM CEM Vero MT-2 HepG2
    D-D4FC H 0.77 1.19 1.15 >100 >100 >100 >50 >100
    35 p-FBz 1.08 0.88 7.2 53.1 51.3 83.1 >50 93.6
    36 p-ClBz 0.48 0.23 1.9 11.9 16.8 72.2 >50 >100
    37 p-BrBz 1.4 0.14 5.2 53 24 40.5 >50 >100
    38 p-IBz 0.76 0.31 0.85 57 11.4 100 >50 >100
    39 m-FBz 7.82 1.0 3.1 45.3 4.2 >100 >50 >100
    40 m-ClBz 1.71 2.0 3.4 45.3 11.2 100 >50 32.4
    41 m-BrBz 1.71 1.0 2.2 51.6 24.9 99.7 >50 >100
    42 p-MeOBz 0.70 0.58 ND >100 ND ND >50 >100
    43 m-MeOBz 2.1 0.34 ND 18.5 24.6 >100 >50 >100
    44 o-MeOBz 14.6 >50 ND 13.1 3.9 5.6 >50 3.4
    45 p-NO2Bz 1.7 0.29 ND 3.4 4.2 6.6 >50 5.6
    46 m-NO2Bz 0.93 0.58 ND 11.9 54.5 >100 >50 >100
    47 o-NO2Bz 39.9 >50 ND 80 >100 >100 >50 >100
    48 p-MeBz 0.32 0.21 ND 13.2 31.9 >100 >50 >100
    49 m-MeBz 0.7 0.8 ND 57.1 34.9 149 >50 >100
    50 o-MeBz 56.8 >50 ND 58.4 46.4 >100 >50 >100
    51 p-EtBz 6.2 0.24 2.3 13 8.1 40.3 >50 >100
    52 p-BuBz 3.1 ND ND 7.3 8.5. 29.4 ND 5.1
    53 p-tBuBz 0.41 0.13 1.1 5 9.9 59.2 >50 >100
    54 o-thiophenecarbonyl 1.6 1.5 ND 10.2 3.9 4.8 >50 2.3
    55 Nicotinoyl 42.3 29 ND 13.8 6.7. 13.1 >50 10.3
    56 benzo[b]thiophene-2- 0.29 0.3 ND 2.2 2.8 5.6 >50 1.3
    carbonyl
    57 cyclopentanecarbonyl 0.40 0.51 ND 52.9 19.6 87.6 >50 >100
    58 Cyclohexanecarbonyl 0.6 0.38 ND 11.7 11.2 >100 >50 >100
    59 Heptanoyl ND 0.23 ND ND ND ND 6.2 ND
    60 Butyryl 1.89 2.4 3.1 52.4 12.2 >100 >50 >100
    ND = not determined

Claims (9)

1-17. (canceled)
18. A compound of formula (I):
Figure US20120202766A1-20120809-C00030
or a pharmaceutically acceptable salt thereof, wherein
i) X is O, S, NR5, CH2, CHF or CF2;
ii) Y is CH2, CHF or CF2;
iii) R1 is chosen from hydrogen, halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, CN, CF3, N3, NO2, aryl, heteroaryl and acyl;
iv) R2 is chosen from alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C6H4R6 where R6 is chosen from halogen, CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl;
v) R3 and R3′ are chosen independently from H, halogen, CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl; and
vi) R4 is H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3′ are H or phosphate, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol.
vii) R5 is H, acyl, alkyl, alkenyl, alkynyl, or cycloalkyl.
19. A pharmaceutical composition that includes an effective HIV or HBV treatment amount of a compound of claim 18 in a pharmaceutically acceptable carrier or diluent.
20. A method for the treatment of a host infected with HIV that includes administering an effective amount of a compound of claim 18 in a pharmaceutically acceptable carrier.
21. A method for the treatment of a host infected with HBV that includes administering an effective amount of a compound of claim 18 in a pharmaceutically acceptable carrier.
22. A method for the treatment of a host infected with HIV that includes administering an effective amount of a compound of claim 18 in a pharmaceutically acceptable carrier in combination with another anti-HIV agent.
23. A method for the treatment of a host infected with HBV that includes administering an effective amount of a compound of claim 18 in a pharmaceutically acceptable carrier in combination with another anti-HBV agent.
24. A compound of claim 18 for use in the treatment of host infected with HIV.
25. A compound of claim 18 for use in the treatment of a host infected with HBV infection.
US13/371,654 2001-12-14 2012-02-13 N4-acylcytosine nucleosides for treatment of viral infections Abandoned US20120202766A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/371,654 US20120202766A1 (en) 2001-12-14 2012-02-13 N4-acylcytosine nucleosides for treatment of viral infections

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34155501P 2001-12-14 2001-12-14
US10/318,511 US7105527B2 (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral infections
US11/461,338 US20070078080A1 (en) 2001-12-14 2006-07-31 N4-Acylcytosine Nucleosides for Treatment of Viral Infections
US11/969,427 US8114997B2 (en) 2001-12-14 2008-01-04 N4-acylcytosine nucleosides for treatment of viral infections
US13/371,654 US20120202766A1 (en) 2001-12-14 2012-02-13 N4-acylcytosine nucleosides for treatment of viral infections

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/969,427 Division US8114997B2 (en) 2001-12-14 2008-01-04 N4-acylcytosine nucleosides for treatment of viral infections

Publications (1)

Publication Number Publication Date
US20120202766A1 true US20120202766A1 (en) 2012-08-09

Family

ID=23338072

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/318,511 Expired - Fee Related US7105527B2 (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral infections
US10/320,350 Ceased US6908924B2 (en) 2001-12-14 2002-12-16 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
US11/461,338 Abandoned US20070078080A1 (en) 2001-12-14 2006-07-31 N4-Acylcytosine Nucleosides for Treatment of Viral Infections
US11/821,076 Expired - Fee Related USRE42015E1 (en) 2001-12-14 2007-06-21 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
US11/969,427 Expired - Fee Related US8114997B2 (en) 2001-12-14 2008-01-04 N4-acylcytosine nucleosides for treatment of viral infections
US13/371,654 Abandoned US20120202766A1 (en) 2001-12-14 2012-02-13 N4-acylcytosine nucleosides for treatment of viral infections

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US10/318,511 Expired - Fee Related US7105527B2 (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral infections
US10/320,350 Ceased US6908924B2 (en) 2001-12-14 2002-12-16 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
US11/461,338 Abandoned US20070078080A1 (en) 2001-12-14 2006-07-31 N4-Acylcytosine Nucleosides for Treatment of Viral Infections
US11/821,076 Expired - Fee Related USRE42015E1 (en) 2001-12-14 2007-06-21 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
US11/969,427 Expired - Fee Related US8114997B2 (en) 2001-12-14 2008-01-04 N4-acylcytosine nucleosides for treatment of viral infections

Country Status (10)

Country Link
US (6) US7105527B2 (en)
EP (1) EP1569652A4 (en)
JP (1) JP2005519916A (en)
KR (1) KR100978904B1 (en)
CN (1) CN100560073C (en)
AU (2) AU2002365234B2 (en)
BR (1) BR0214944A (en)
CA (1) CA2470255C (en)
MX (1) MXPA04005779A (en)
WO (2) WO2003063771A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
BR0110023A (en) 2000-04-13 2003-12-30 Pharmasset Ltd Substituted 3'-or-2 'nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (en) * 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 Methods and compositions for treating flaviviruses and pestiviruses
US7105527B2 (en) * 2001-12-14 2006-09-12 Otto Michael J N4-acylcytosine nucleosides for treatment of viral infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CA2489552A1 (en) * 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN101172993A (en) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0313164A (en) 2002-08-01 2007-07-17 Pharmasset Inc compounds with the non-bicyclic system [4.2.1] for the treatment of flaviviridae infections
MXPA05005192A (en) * 2002-11-15 2005-09-08 Idenix Cayman Ltd 2aCOE-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE.
WO2004052899A2 (en) * 2002-12-12 2004-06-24 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
SI3521297T1 (en) 2003-05-30 2022-04-29 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US7741334B2 (en) * 2004-04-01 2010-06-22 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
CN101023094B (en) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
ES2725457T3 (en) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparation of ribofuranosyl pyrimidines and 2'fluoro-2'-alkyl-substituted or other optionally substituted purines and their derivatives
CA2584670A1 (en) * 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US7968703B2 (en) 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
WO2007075876A2 (en) * 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
KR101715981B1 (en) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
DE202012013382U1 (en) 2011-09-16 2016-08-23 Gilead Pharmasset Llc Compositions for the treatment of HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103242400B (en) * 2012-02-08 2016-06-08 河南师范大学 There is 5-substituted pyrimidines nucleoside-thiazolidhybrid hybrid and its preparation method of HIV (human immunodeficiency virus)-resistant activity
PT2950786T (en) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
SI3650014T1 (en) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PL3512863T3 (en) 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
KR102335193B1 (en) 2017-02-01 2021-12-03 아테아 파마슈티컬즈, 인크. Nucleotide hemi-sulfate salts for treating hepatitis C virus
KR20200140865A (en) 2018-04-10 2020-12-16 아테아 파마슈티컬즈, 인크. Treatment of HCV-infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908924B2 (en) * 2001-12-14 2005-06-21 Pharmasset, Inc. N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13660A (en) * 1855-10-09 Improvements
US3309359A (en) * 1965-10-22 1967-03-14 Hoffmann La Roche N-mono-acyl-5-fluorocytosine derivatives and process
NL8202626A (en) 1982-06-29 1984-01-16 Stichting Rega V Z W DERIVATIVES OF 9- (2-HYDROXYETHOXYMETHYL) GUANINE.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA886890B (en) * 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
NL8901258A (en) 1989-05-19 1990-12-17 Stichting Rega V Z W New 5-halo-2'-3'-di:deoxy-cytidine derivs. - useful as anti-retro-viral agents, esp. for treating HIV infections
DD293498A5 (en) 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De METHOD FOR PRODUCING A MEDIUM FOR THE TREATMENT OR PROPHYLAXIS OF HEPATITE INFECTIONS IN HUMANS AND ANIMALS
JPH05310777A (en) 1992-05-14 1993-11-22 Yoshitomi Pharmaceut Ind Ltd 2'-deoxy-2'-methylidynecytidine compound
TW254946B (en) * 1992-12-18 1995-08-21 Hoffmann La Roche
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
GB9525606D0 (en) * 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
WO1998017281A1 (en) * 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
EP1042341A1 (en) * 1997-11-25 2000-10-11 Protarga Inc. Nucleoside analog compositions and uses thereof
DE69933860T2 (en) * 1998-02-25 2007-05-31 Emory University 2'-FLUORONUKLEOSIDE
JP2004510832A (en) * 2000-10-13 2004-04-08 シャイアー・バイオケム・インコーポレイテッド Dioxolane analogs for improved cell-to-cell delivery
KR20040028657A (en) * 2000-10-18 2004-04-03 파마셋, 리미티드 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908924B2 (en) * 2001-12-14 2005-06-21 Pharmasset, Inc. N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
US7105527B2 (en) * 2001-12-14 2006-09-12 Otto Michael J N4-acylcytosine nucleosides for treatment of viral infections
USRE42015E1 (en) * 2001-12-14 2010-12-28 Pharmasset, Inc. N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Also Published As

Publication number Publication date
US7105527B2 (en) 2006-09-12
KR20040094398A (en) 2004-11-09
USRE42015E1 (en) 2010-12-28
MXPA04005779A (en) 2005-05-16
EP1569652A4 (en) 2008-07-02
KR100978904B1 (en) 2010-08-31
WO2003051306A2 (en) 2003-06-26
AU2002364730A1 (en) 2003-06-30
BR0214944A (en) 2005-06-07
US20090176730A1 (en) 2009-07-09
US20030176319A1 (en) 2003-09-18
US8114997B2 (en) 2012-02-14
CN1617726A (en) 2005-05-18
WO2003063771A3 (en) 2005-07-07
WO2003051306A3 (en) 2003-12-18
WO2003063771A2 (en) 2003-08-07
CN100560073C (en) 2009-11-18
US20040214844A1 (en) 2004-10-28
AU2002365234B2 (en) 2009-01-29
EP1569652A2 (en) 2005-09-07
JP2005519916A (en) 2005-07-07
AU2002364730A8 (en) 2003-06-30
CA2470255C (en) 2012-01-17
US6908924B2 (en) 2005-06-21
US20070078080A1 (en) 2007-04-05
CA2470255A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
US8114997B2 (en) N4-acylcytosine nucleosides for treatment of viral infections
AU2002365234A1 (en) N4-acylcytosine nucleosides for treatment of viral infections
KR101939710B1 (en) Hepatitis b antiviral agents
TWI568734B (en) Dihydropyrimidine-fused cyclic dericatives as hepatitis b virus (hbv) inhibitors
KR101940831B1 (en) (alpha-substituted aralkylamino and heteroarylalkylamino)pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CA2685748A1 (en) Azido purine nucleosides for treatment of viral infections
WO2014135107A1 (en) Novel nucleoside phosphoramidate compound and use thereof
WO2011069294A1 (en) N6-substituted adenosine derivatives, n6-substituted adenine derivatives and uses thereof
US8815829B2 (en) 3′-azido purine nucleotide prodrugs for treatment of viral infections
EP3523292B1 (en) Heteroaryl compounds and their use as mer inhibitors
EP3398598B1 (en) Sulfonamide derivative and preparation method and use thereof
KR20070059156A (en) Dna-pk inhibitors
TWI741055B (en) The pharmaceutical compositions for the prevention and treatment of the nash, liver fibrosis and liver cirrhosis containing adenosine derivatives
CA3190495A1 (en) Compounds, compositions and methods
JP2022531899A (en) Modified cyclic dinucleoside compound as a STING modulator
EA036892B1 (en) Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CN112851583A (en) Novel benzazepine compounds, compositions and uses thereof
JPWO2018110591A1 (en) 2&#39;-deoxy-7-deazapurine nucleoside derivatives having antiviral activity
BRPI0924084A2 (en) pyrazine derivatives useful as atr kinase inhibitors.

Legal Events

Date Code Title Description
AS Assignment

Owner name: GILEAD PHARMASSET LLC, CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:PHARMASSET, INC.;REEL/FRAME:028081/0686

Effective date: 20120210

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION